# Single-deletion-mutant, third-generation rabies viral vectors allow nontoxic retrograde targeting of projection neurons with greatly increased efficiency 

Lei Jin ${ }^{1}$, Heather A. Sullivan ${ }^{1}$, Mulangma Zhu ${ }^{1}$, Nicholas E. Lea ${ }^{1}$, Thomas K. Lavin ${ }^{1}$, Makoto Matsuyama ${ }^{1}$, YuanYuan Hou ${ }^{1}$, and lan R. Wickersham ${ }^{1 *}$

1. McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA
*Correspondence.

## SUMMARY

Rabies viral vectors have become important components of the systems neuroscience toolkit, allowing both direct retrograde targeting of projection neurons and monosynaptic tracing of inputs to defined postsynaptic populations, but the rapid cytotoxicity of firstgeneration ( $\Delta \mathrm{G}$ ) vectors limits their use to short-term experiments. We recently introduced second-generation, double-deletion-mutant ( $\Delta \mathrm{GL}$ ) rabies viral vectors, showing that they efficiently retrogradely infect projection neurons and express recombinases effectively but with little to no detectable toxicity; more recently, we have shown that $\Delta \mathrm{GL}$ viruses can be used for monosynaptic tracing with far lower cytotoxicity than the first-generation system. Here we introduce third-generation ( $\Delta \mathrm{L}$ ) rabies viral vectors, which, like first-generation vectors, have only a single gene deleted from their genomes (in this case the viral polymerase gene L) but which appear to be as nontoxic as second-generation ones: using longitudinal structural and functional two-photon imaging in mouse visual cortex in vivo, we found that they did not kill labeled neurons or noticeably perturb their response properties over the entire months-long courses of imaging. Although third-generation vectors are therefore phenotypically very similar to second-generation ones, we show that they have the major advantage of growing to much higher titers, and this key difference results in 25\% $525 \%$ increased numbers of retrogradely labeled neurons in vivo. These $\Delta \mathrm{L}$ rabies viral vectors therefore constitute a new state of the art for minimally perturbative, pathwayspecific expression of recombinases and transactivators in mammalian neurons selected on the basis of their axonal projections. Because replication of deletion-mutant rabies viruses within complementing cells is precisely the process that underlies monosynaptic tracing, the higher replication efficiency of this new class of rabies viral vectors furthermore suggests the potential to provide the foundation of an improved nontoxic monosynaptic tracing system.

## INTRODUCTION

Since their introduction to neuroscience in 2007 (Wickersham et al., 2007a; Wickersham et al., 2007b), recombinant rabies viral vectors have become widely-adopted tools in neuroscience, allowing "monosynaptic tracing" of direct inputs to genetically-targeted starting postsynaptic neuronal populations (Jin et al., 2021b; Wall et al., 2010; Wickersham et al., 2007b) as well as simple retrograde targeting of projection neurons when injected at the sites of these projection neurons' axonal arborizations (Chatterjee et al., 2018; Wickersham et al., 2007a). These vectors are now used in a large number of laboratories worldwide and have contributed to many high-impact studies of a wide variety of neural systems (Foster et al., 2021; Miyamichi et al., 2011; Reardon et al., 2016; Schwarz et al., 2015; Siu et al., 2021; Smith et al., 2021; Stephenson-Jones et al., 2016; Wu et al., 2021; Yao et al., 2021).

Because first generation (" $\Delta \mathrm{G}$ ") rabies viral vectors (which have only the glycoprotein gene G deleted from their genomes) are cytotoxic (Chatterjee et al., 2018; Jin et al., 2021a; Jin et al., 2021b; Wickersham et al., 2007a), we recently introduced second-generation, " $\Delta \mathrm{GL}$ " rabies viral vectors, which have both the glycoprotein gene G and the viral polymerase gene L (for "large" protein) deleted from their genomes (Chatterjee et al., 2018). Because the viral polymerase is absolutely required for transcription of all genes
from the rabies viral genome as well as for replication of the viral genome itself (Albertini et al., 2011; Finke and Conzelmann, 2005; Horwitz et al., 2020; Morin et al., 2013; Ogino and Green, 2019; Te Velthuis et al., 2021), this additional deletion, by design, reduces gene expression to a minimal level (provided by the few starting copies of the polymerase protein that are copackaged in each viral particle) that appears to be completely harmless to the "infected" cells. Because transgene expression is reduced by the same degree, we inserted the genes for Cre and Flpo recombinase, of which even low levels of expression are sufficient to cause neuroscientifically-useful downstream effects such as expression of fluorophores or calcium indicators in labeled cells (Chatterjee et al., 2018). We originally showed that these $\Delta \mathrm{GL}$ vectors are useful tools for retrograde targeting of projection neurons (Chatterjee et al., 2018), and they have since been used as such for applications including optogenetics and transcriptomic profiling (Ren et al., 2021; Roy et al., 2021; Tasic et al., 2018). More recently, we have also shown that $\Delta G L$ vectors can be complemented in vivo by expression of both $G$ and $L$ in trans, yielding a second-generation monosynaptic tracing system with far lower cytotoxicity than the first-generation version (Jin et al., 2021a).

Here we show that deletion of $L$ alone appears to make rabies viral vectors as nontoxic as $\Delta G L$ ones, with labeled neurons surviving for at least months with apparently unperturbed visual response properties. We find that these $\Delta \mathrm{L}$ vectors have a major growth advantage over $\Delta \mathrm{GL}$ ones in cell culture, attaining much higher titers in complementing cells in culture. This higher replication efficiency translates into the practical advantage of retrogradely labeling many more projection neurons when injected into these neurons' target sites in vivo.

## RESULTS

## Construction and characterization of $\Delta \mathrm{L}$ rabies virus

We began by constructing rabies viral vectors with only the polymerase gene deleted and characterized their gene expression levels and growth dynamics in cell culture (Figure 1). Beginning with the genome plasmid of a $\Delta \mathrm{GL}$ virus (Chatterjee et al., 2018), we reinserted the native glycoprotein gene in its original location, followed by the gene for Cre recombinase (codon-optimized for mouse (Koresawa et al., 2000)) in an additional transcriptional unit, then produced infectious virus by standard techniques (see Methods). We then compared the gene expression levels of the resulting virus, RV $\Delta \mathrm{L}-\mathrm{Cr}$, to those of first- and secondgeneration versions (RVAG-Cre and RVAGL-Cre, respectively) in cell culture (HEK 293T/17 cells) using immunostaining for Cre as well as for the viral nucleoprotein, the highest-expressed rabies viral protein.

As shown in Figure 1A-D, whereas the first-generation ( $\Delta \mathrm{G}$ ) virus expressed high levels of nucleoprotein (which accumulated in cytoplasmic inclusions) and Cre (which localized to the nuclei), the $\Delta \mathrm{GL}$ and $\Delta L$ viruses had very low expression levels of both Cre and nucleoprotein, with the amount of label for these proteins appearing much more similar to that seen in uninfected control cells than in cells infected with the $\Delta \mathrm{G}$ virus. We also found similarly low transgene expression levels for $\Delta \mathrm{L}$ and $\Delta \mathrm{GL}$ viruses expressing EGFP (Figure S1). However, just as we found previously for $\Delta \mathrm{GL}$ viruses (Chatterjee et al., 2018), the Cre expressed by RV $\Delta \mathrm{L}$-Cre was sufficient to result in bright labeling of Cre reporter cells (bottom row in panels A-D).

These results led us to predict that $\Delta \mathrm{L}$ viruses would be as nontoxic as $\Delta G L$ ones, because of their similarly low expression levels, and also that they would be similarly able to recombine reporter alleles in vivo in order to allow downstream expression of useful transgene products such as fluorophores, activity indicators, or opsins.

It remained to be seen, however, whether $\Delta \mathrm{L}$ viruses would have any particular advantage over $\Delta \mathrm{GL}$ ones for purposes of retrogradely targeting neurons. Specifically, if they could not be produced at significantly higher titers, they could be expected to label similar numbers of projection neurons, making $\Delta \mathrm{L}$ vectors a mere curiosity of purely academic interest and with no relevance to neuroscientists. However, if they could be grown to much higher titers than $\Delta \mathrm{GL}$ vectors, that could be expected to translate to the ability to retrogradely label many more projection neurons, a desirable characteristic indeed for a tool for retrograde targeting.

To examine this, we directly compared the ability of $\Delta \mathrm{L}$ virus to replicate in complementing cells with that of $\Delta G L$ and $\Delta G$ viruses (Figure 1E-F). We infected cell lines expressing L, G, or both with the three different generations of virus, at two different multiplicities of infection (MOI, measured in infectious units per cell): either very low (MOI = 0.01, "multi-step growth curves" (Gomme et al., 2010; Wang and Bushman, 2006)) or high (MOI = 1, "single-step growth curves". Following a one-hour incubation in the presence of the
viruses, we washed the cells twice with DPBS and applied fresh medium, then collected supernatant samples every 24 hours for five days after infection, then titered the samples on reporter cells.

As seen in Figure 1E-F, the results were clear: whereas the $\Delta \mathrm{GL}$ virus (on cells expressing both $G$ and L ) never accumulated to titers higher than $2.37 \mathrm{e} 6 \mathrm{iu} / \mathrm{mL}$ in either experiment, the $\Delta \mathrm{L}$ virus grew to maximal titers of $6.51 \mathrm{e} 6 \mathrm{iu} / \mathrm{mL}$ (at MOI of 0.01 ) and $1.96 \mathrm{e} 7 \mathrm{iu} / \mathrm{mL}$ (at MOI of 1 ) on the same cell line (expressing both G and L ) and considerably higher (maximal titers of $1.31 \mathrm{e} 7 \mathrm{iu} / \mathrm{mL}$ at $\mathrm{MOI}=0.01$ and 2.60 e 7 $\mathrm{iu} / \mathrm{mL}$ at $\mathrm{MOI}=1$ ) on cells expressing L alone. The $\Delta \mathrm{G}$ virus grew to similarly high (or slightly higher, in the $\mathrm{MOI}=1$ case) titers to the $\Delta \mathrm{L}$ one: $6.83 \mathrm{e} 6 \mathrm{iu} / \mathrm{mL}$ at $\mathrm{MOI}=0.01$ and $3.03 \mathrm{e} 7 \mathrm{iu} / \mathrm{mL}$ at $\mathrm{MOI}=1$, suggesting that single-deletion-mutant rabies viruses may in general be easier to make at high titers than viruses with multiple deleted genes. In non-complementing cells, by contrast, no such replication of any of these viruses ( $\Delta \mathrm{L}, \Delta \mathrm{GL}$, or $\Delta \mathrm{G}$ ) occurred (Figure S2).

These findings that a $\Delta \mathrm{L}$ rabies virus could be grown to 11 -fold higher titer than a matched $\Delta \mathrm{GL}$ one led us to predict that $\Delta \mathrm{L}$ viruses would be superior tools for retrograde targeting in vivo, because their much higher titers would result in retrograde infection of many more projection neurons.

## Retrograde targeting in vivo

To test this prediction, we made matched preparations of $\Delta \mathrm{GL}$ and $\Delta \mathrm{L}$ viruses expressing either Cre or Flpo (mouse-codon-optimized Flp recombinase (Raymond and Soriano, 2007)), then injected each of the four viruses in the somatosensory thalami of reporter mice (Ai14 (Madisen et al., 2010) for the Cre viruses, Ai65F (Daigle et al., 2018) for the Flpo ones; both lines express tdTomato following recombination by the respective recombinase). We sacrificed the mice at either 7 days or 4 weeks after injection, sectioned and imaged the brains by confocal microscopy, and counted the numbers of retrogradely labeled cells in cortex. Figure 2 shows the results.

As seen in panels 2B-E, for both recombinases, and at both timepoints, the $\Delta \mathrm{L}$ viruses significantly outperformed the $\Delta G L$ ones. For the Flpo viruses, the difference was dramatic: at the 1 -week timepoint, the $\Delta \mathrm{L}$ virus labeled 24 times as many cells as the $\Delta \mathrm{GL}$ one (although this difference was not statistically significant due to high variance in the $\Delta \mathrm{L}$ cohort: single factor ANOVA, $\mathrm{p}=0.275, \mathrm{n}=8$ mice each group); by the 4 -week timepoint, the $\Delta \mathrm{L}$-Flpo virus had labeled 6.25 times as many cells as the $\Delta \mathrm{GL}$ counterpart, a difference that was extremely significant (single factor ANOVA, $\mathrm{p}=3.21 \mathrm{E}-04, \mathrm{n}=8$ mice each group). For the Cre viruses, the difference was smaller, presumably due a ceiling effect (see Discussion), but still highly significant: at 1 week, the $\Delta \mathrm{L}$-Cre virus had labeled 1.40 times as many cells as $\Delta \mathrm{GL}$-Cre (single factor ANOVA, $p=4.20 \mathrm{E}-03$; $\mathrm{n}=4$ mice each group); at the 4 -week timepoint, the $\Delta \mathrm{L}$-Cre virus had labeled 1.25 times as many cells as $\Delta \mathrm{GL}$-Cre (single factor ANOVA, $\mathrm{p}=7.38 \mathrm{E}-04, \mathrm{n}=4$ mice per group).

We also made some injections of RV $\Delta \mathrm{L}-\mathrm{Cre}$, in thalami of Ai14 mice, with the much longer survival times of 4 or 6 months (Fig 2F-G). The results at both of these longer survival times appeared very similar to those at the shorter ones. Consistent with extensive prior literature on corticothalamic neurons (Alitto and Usrey, 2003; Rockland, 2021; Rouiller and Welker, 2000) and with our previous results with corticothalamic injections of $\Delta \mathrm{G}$ and $\Delta \mathrm{GL}$ viruses (Chatterjee et al., 2018; Wickersham et al., 2007a), the cells labeled in cortex by both viruses at all timepoints were pyramidal neurons in layer 6 , with a few in layer 5 . Furthermore, labeled neurons all appeared morphologically normal even months after injection, with the fine processes of axons and dendrites, including individual spines (rightmost images in 2F-G) clearly visible and without blebbing or other obvious abnormalities.

As a further test of the flexibility of $\Delta \mathrm{L}$ vectors, we made a version expression the tetracycline transactivator (tTA) and injected it in the thalamus of Ai63 reporter mice (in which TRE-tight drives tdTomato expression) (Daigle et al., 2018). As seen in Figure S3, thousands of cortical thalamic cells were found retrogradely labeled at both 1 -week and 4 -week survival times, with no significant difference between the numbers at the two timepoints (single factor ANOVA, $\mathrm{p}=0.772, \mathrm{n}=4$ mice per group).

## Longitudinal structural two-photon imaging in vivo

Because examining only postmortem tissue can be very misleading when attempting to determine whether a virus is nontoxic (see Jin et al. '21 (Jin et al., 2021a) for a detailed case study), we conducted longitudinal two-photon imaging of RV $\Delta L$-labeled neurons in vivo (Figure 3). We injected either RV $\Delta$ GL-Cre (Chatterjee et al., 2018) or RV $\Delta \mathrm{L}$-Cre in primary visual cortex (V1) of Ai14 reporter mice, then imaged the resulting tdTomato-expressing neurons at or near the injection site beginning 7 days after injection and continuing every 7 or 14 days until 16 weeks postinjection. As seen in Figure 3, the results using the two viruses were very similar. For both $\Delta \mathrm{GL}$ and $\Delta \mathrm{L}$ viruses, the numbers of visibly labeled neurons increased significantly
between 1 week and 4 weeks postinjection (Figure 3D, G), by $56.27 \%$ for $\Delta G L$ and by $67.77 \%$ for $\Delta L$ (paired t-tests, $\mathrm{p}=1.319 \mathrm{E}-04$ for $\Delta \mathrm{GL}, \mathrm{p}=1.003 \mathrm{E}-05$ for $\Delta \mathrm{L}, \mathrm{n}=8 \mathrm{FOVs}$ for each virus). Also for both viruses, the numbers of visibly labeled neurons remained nearly completely constant from the 4 -week timepoint onward through all remaining imaging sessions (Figure 3E, H) (with the number of labeled cells at the 4-week timepoint being not significantly different than that at the 12 -week timepoint for the $\Delta \mathrm{L}$ virus (paired t -test, p $=0.1327, n=8$ FOVs) and slightly ( $0.5 \%$ ) lower for the $\Delta G L$ virus (paired t-test, $p=0.0056, n=8$ FOVs). See File S3 for all counts and statistical comparisons; see also Video S1 for a rendering of a group of $\Delta \mathrm{L}$ labeled neurons at 2 weeks and again at 10 weeks.

## Longitudinal functional two-photon imaging in vivo

We went on to examine the functional properties of RVDL-labeled neurons in vivo. As for the structural imaging (see above), we injected RV $\Delta \mathrm{L}-$ Cre in the primary visual cortices of reporter mice, in this case mice that express the calcium indicator GCaMP6s (Chen et al., 2013) after Cre recombination (Figure 4). Beginning one week later, we began imaged the calcium signals in the labeled neurons in a series of imaging sessions that continued until 16 weeks postinjection, in the awake mice viewed visual stimuli consisting of drifting gratings of different orientations and frequencies. Just as we found previously for $\Delta G L$ viruses (Chatterjee et al., 2018; Jin et al., 2021b), we found no signs of dysfunction in cells labeled by the thirdgeneration vector for as long as we followed them (Figure 4; see also Figures S4 and S5. See File S4 for all counts and statistical comparisons and Video S2 for an example of calcium responses in a group of cortical neurons 16 weeks after injection of RV $\Delta L-C r e$ ).

## DISCUSSION

Here we have shown that deletion of just the polymerase gene renders rabies viral vectors nontoxic, like second-generation ( $\Delta \mathrm{GL}$ ) vectors, but makes them much more efficient at replicating within complementing cells in culture. This ability to be grown to much higher titers results in significantly increased transduction of projection neurons within a given pathway. This more comprehensive access to projection neurons will increase the yield and efficacy of systems neuroscience experiments that depend on the retrograde targeting approach.

In the corticothalamic pathway that we have examined here, the advantage of a $\Delta \mathrm{L}$ vector over the $\Delta G L$ equivalent was clearest in the case of the Flpo-expressing versions, with the $\Delta L$ vector labeling 6.25 times as many neurons as the $\Delta \mathrm{GL}$ one did at four weeks postinjection. This ratio is of the same order of magnitude as the ratio of the titers of the injected Flpo viruses (14.4: see Methods). By contrast, for the Creexpressing versions, the advantage of the $\Delta \mathrm{L}$ vector over the $\Delta \mathrm{GL}$ one was more modest, labeling 1.25 times as many cells, even though the ratio of the titers of these Cre vectors was even higher (20.5). Because the absolute numbers of retrogradely labeled neurons, as well as the titers, were much higher for the Cre viruses than for the corresponding Flpo ones, we presume that the smaller advantage of the $\Delta \mathrm{L}$ version seen in this case was because of a ceiling effect, with the $\Delta$ GL-Cre virus already labeling most of the available neurons in this pathway.

One could certainly argue that the much higher titers that we are easily able to obtain with $\Delta L$ vectors could also, in theory, potentially be achieved with $\Delta \mathrm{GL}$ vectors, if enough effort were put into generating and testing producer cell lines expressing both $G$ and $L$ in order to find one that expressed the two genes at just the right ratio and levels. In practice, however, this hypothetical future research effort does not detract from the fact that the best currently-existing preparations of $\Delta \mathrm{L}$ rabies viral vectors label many more cells than do $\Delta \mathrm{GL}$ ones, making them the better choice for retrograde targeting applications.

We note that, although here we have only demonstrated the use of $\Delta \mathrm{L}$ rabies viral vectors in mice, they are also highly likely to work in a wide variety of mammalian species, because, apart from their shorter RNA genomes, the structural properties of second- and third-generation rabies viral particles are identical to those of first-generation ones, which have been successfully used in diverse mammalian species including rats (Cruz et al., 2021), cats (Connolly et al., 2012; Liu et al., 2013), ferrets (Hasse et al., 2019), and macaques (Bragg et al., 2017; Briggs et al., 2016; Lyon et al., 2010; Nassi and Callaway, 2006, 2007; Nassi et al., 2006; Siu et al., 2021; Yarch et al., 2017) (and even in fish (Dohaku et al., 2019; Satou et al., 2021; Zhu et al., 2009) and frogs (Faulkner et al., 2021)).

Our findings here that $\Delta \mathrm{L}$ rabies viruses have extremely low expression levels and do not replicate within (or spread beyond, in vivo) non-complementing cells are entirely consistent with similar findings in cell culture in a recent report on an L-deficient rabies virus encoding firefly luciferase (Nakagawa et al., 2017).

A note about safety: our results strongly suggest that $\Delta \mathrm{L}$ rabies viruses are unable to replicate in the absence of complementation and moreover are harmless to any cells that they transduce. However, a mixture of $\Delta L$ and $\Delta G$ viruses could pose a safety risk, because such viruses will be mutually complementary. Care must therefore be taken to avoid contamination between $\Delta \mathrm{L}$ and $\Delta \mathrm{G}$ constructs - either packaged viruses or the genome plasmids used to make them - which would have the potential to create a selfcomplementing replication-competent mixture (see Hidaka et al. (Hidaka et al., 2018) for an example of such a self-complementing mixture).

Finally, we have recently shown (Jin et al., 2021b) that second-generation ( $\Delta \mathrm{GL}$ ) rabies viral vectors can spread transsynaptically when complemented by provision of both $G$ and $L$ in trans. That is, complementation of an L-deficient rabies virus (in that case, a G- and L-deficient virus that is also complemented by G) allows it to spread beyond initially infected cells in vivo. It is therefore reasonable to infer that provision of $L$ in trans should allow third-generation, $\Delta L$ rabies viral vectors to spread beyond initially infected cells, given that we have shown here that such complementation in cell culture allows $\Delta \mathrm{L}$ viruses to replicate very efficiently. We have also shown here, with the longitudinal two-photon imaging of labeled neurons, that $\Delta \mathrm{L}$ viruses do not spread beyond initially infected cells in vivo in the absence of complementation. Collectively, our results therefore suggest the outlines of a third-generation monosynaptic tracing system based on $\Delta L$ vectors complemented with $L$ expression in trans. However, genetic targeting of a $\Delta L$ vector to specific starting cell types might appear elusive: in the first- and second-generation systems (Jin et al., 2021b; Wickersham et al., 2007b), this targeting is achieved by packaging the rabies viral particles with an avian retroviral envelope protein (EnvA) instead of its own envelope glycoprotein, so that they can only infect cells that have been engineered to express EnvA's cognate receptor. On the face of it, this pseudotyping strategy requires that $G$ be deleted from the rabies viral genome, because expression of $G$ by the virus within the EnvA-expressing producer cells would result in the production of virions with membranes populated by a mixture of EnvA and the rabies viral glycoprotein. If this challenge could be overcome, our present findings that $\Delta \mathrm{L}$ viruses replicate more readily in complementing cells, which is the fundamental process central to monosynaptic tracing (Wickersham et al., 2007b), suggest that a third-generation monosynaptic tracing system could be more efficient than the second-generation one.

## METHODS

All experiments involving animals were conducted according to NIH guidelines and approved by the MIT Committee for Animal Care. Mice were housed 1-5 per cage under a normal light/dark cycle for all experiments.

## Cloning

The third-generation rabies viral vector genome plasmids $p R V \Delta L-5 C r e, p R V \Delta L-5 F l p o$, and $p R V \Delta L-5 t T A$ (Addgene 182964, 182965, and 182966) (the " 5 " denoting the position of the transgene relative to the other genes in the viral genome) was made by replacing the mCre gene in pRV $\Delta$ GL-4Cre (Chatterjee et al., 2018) (Addgene 98039) with the SAD B19 glycoprotein gene from pCAG-B19G (Chatterjee et al., 2018) (Addgene 59921) and either the mCre, Flpo (from pRV $\Delta$ G-4Flpo (Addgene 98040)), or tTA (from pAAV-syn-FLEX-splitTVA-EGFP-tTA (Liu et al., 2017) (Addgene 100798)) gene, separated by endogenous rabies viral transcriptional stop and start signals, using seamless cloning (InFusion (Takara) or HiFi (NEB)).

The piggyBac vector pB-TREtight-EGFP (Addgene 182967) was made by cloning the TRE-tight element from pAAV-TREtight-mTagBFP2-B19G (Liu et al., 2017) and the EGFP gene into pB-CAG-TEVp-IRES-mCherry (Addgene 174377) in place of the CAG-TEVp-IRES-mCherry sequences using HiFi seamless cloning (NEB).

The piggyBac plasmid pB-CAG-B19G-IRES-EGFP-WPRE-BGHpA (Addgene 178517) was made by cloning the CAG promoter from pCAG-B19G (Addgene 59921), the SAD B19 L gene, the EMCV IRES (Gallardo et al., 1997), the mCherry (Shaner et al., 2004) gene, and the woodchuck post-transcriptional regulatory element and bovine growth hormone polyadenylation signal from pCSC-SP-PW-GFP (Addgene 12337), into PB-CMV-MCS-EF1-Puro (System Biosciences \#PB510B-1).

## Cell lines

The BHK-B19G3 cell line, expressing the SAD B19 strain rabies virus glycoprotein gene, was made by resorting BHK-B19G2 cells (Wickersham et al., 2010) on a BD Facs Aria cell sorter and retaining the
brightest 2\% of EGFP-positive cells as well as the next-brightest 18\%. Following the sort, both populations were expanded and refrozen, then thawed and tested for their efficacy at supporting replication of $\Delta \mathrm{G}$ virus; the second-brightest population ("BHK-B19G3_2") was found to result in higher titers and is referred to here as BHK-B19G3.

The BHK-B19L cell line, expressing the SAD B19 strain rabies virus polymerase gene, was made by transfecting BHK-21 cells (ATCC CCL-10) with pCAG-hypBase (Jin et al., 2021a) and pB-CAG-B19L-IRES-mCherry-WPRE-BGHpA (Jin et al., 2021b) using Lipofectamine 2000 (Thermo Fisher 11668019), then expanding the cells and sorting on a FACS Aria sorter (BD) to collect the brightest $5 \%$, as well as the next brightest $5 \%$, of mCherry-expressing cells. The two collected populations were expanded and refrozen, then thawed and tested for their efficacy at supporting replication of $\Delta \mathrm{L}$ virus; the second-brightest population ("BHK-B19L_2") was found to result in higher titers and is referred to here as BHK-B19L.

The BHK-B19L-G cell line, expressing the SAD B19 strain rabies virus polymerase and glycoprotein genes, was made by transfecting BHK-B19L cells (see above) with pCAG-hypBase and pB-CAG-B19G-IRES-EGFP-WPRE-BGHpA (see above), then expanding and sorting on a BD FACS Aria, keeping the brightest $5 \%$, as well as the next brightest $5 \%$, of EGFP-expressing cells which also expressed mCherry. The sorted cells were expanded and refrozen, then thawed and tested for their efficacy at supporting replication of $\Delta G L$ virus; the brightest population ("BHK-B19L-G_1") was found to result in higher titers and is referred to here as BHK-B19L-G.

The 293T-TREtight-EGFP cell line for titering tTA-expressing viruses was made by transfecting HEK 293T/17 cells with pCAG-hypBase and pB-TREtight-EGFP (described above), then expanded and sorted on a BD FACS Aria, excluding the brightest $2 \%$ of EGFP cells, and keeping four of the next brightest EGFP cell populations. The sorted cells were expanded, frozen, and then thawed for testing their efficacy at titering $\Delta \mathrm{L}$-tTA virus. The fourth-brightest tranche of cells was used for subsequent titering of $\Delta \mathrm{L}$-tTA virus.

## Rabies virus production and titering

The first-generation vector RV $\Delta G-4$ Cre, the second-generation vectors RV $\Delta G L-4 C r e$ and $R V \Delta G L-4 F I p o$, and the third-generation vectors RV $\Delta \mathrm{L}-5 \mathrm{Cre}, \mathrm{RV} \Delta \mathrm{L}-5 \mathrm{Flpo}$, and $\mathrm{RV} \Delta \mathrm{L}-5 \mathrm{tTA}$ were rescued as described previously (Chatterjee et al., 2018) using genome plasmids pRV $\Delta$ GL-4Cre, pRV $\Delta$ GL-4Flpo, pRV $\Delta L-5 C r e$, $p R V \Delta L-5 F l p o$, and $p R V \Delta L-5 t T A$, respectively. For simplicity, these viruses are referred to in this manuscript as RV $\Delta \mathrm{G}-\mathrm{Cre}, \mathrm{RV} \Delta \mathrm{GL}-\mathrm{Cre}, \mathrm{RV} \Delta \mathrm{GL}-\mathrm{Flpo}$, RV $\Delta \mathrm{L}-\mathrm{Cre}, \mathrm{RV} \Delta \mathrm{L}-\mathrm{Flpo}$, and RV , L-tTA, omitting the numbers denoting the positions of the transgenes within the viral genomes. Rescue supernatants were collected and filtered as described (Wickersham and Sullivan, 2015), titered on the reporter cell lines 293T-FLEX BC (for Cre viruses) or 293T-F14F15S-BC (for Flpo viruses) (Jin et al., 2021a) as described (Wickersham et al., 2010), then used to infect BHK-B19G3, BHK-B19L-G, or BHK-B19L cells (see above) at multiplicities of infection ranging from 0.1 to 1 . Supernatants from these "P1" plates were collected and titered as described (Wickersham and Sullivan, 2015); in some cases, these were used for a similar second passage ("P2"). Purification and concentration of either P1 or P2 supernatants was as described (Wickersham et al., 2010), with supernatants treated with benzonase (Sigma 71206) ( 25 minute incubation at $37^{\circ} \mathrm{C}$ with 30 units $/ \mathrm{ml}$ at) before ultracentrifugation. Concentrated viruses were aliquoted and frozen at $-80^{\circ} \mathrm{C}$. Rabies viruses were titered on reporter cells (293T-FLEX-BC for Cre viruses, 293T-F14F15S-BC for Flpo viruses, 293T-TREtight-EGFP (see above) for RVAL-tTA) as described (Wickersham et al., 2010), using a LUNA-II cell counter (Logos Biosystems) instead of a hemocytometer for counting cells, and in some cases using two-fold (as opposed to ten-fold) dilution series for more precise comparisons of titers.

## Immunostaining, imaging, and flow cytometry of cultured cells

For anti-nucleoprotein and anti-Cre staining (for Figure 1): HEK 293T/17 (ATCC 11268) cells were plated on poly-L-lysine-coated coverslips in 24 -well plates, then infected the following day with serial dilutions of RV $\Delta \mathrm{G}-4$ Cre (Chatterjee et al., 2018), RV $\Delta \mathrm{GL}-4$ Cre (Chatterjee et al., 2018), or RV $\Delta L-5 C r e$. Three days after infection, cells were fixed with $2 \%$ paraformaldehyde, washed repeatedly with blocking/permeabilization buffer ( $0.1 \%$ Triton-X (Sigma) and 1\% bovine serum albumin (Sigma) in PBS), then labeled with a 1:100 dilution of anti-nucleoprotein monoclonal antibody blend (Light Diagnostics Rabies DFA Reagent, EMD Millipore 5100) as well as a 1:250 dilution of rabbit anti-Cre polyclonal antibody (Millipore Sigma 69050) followed by a 1:200 dilution of Alexa Fluor 594-conjugated donkey anti-rabbit secondary (Jackson Immuno 711-585-152).

For anti-EGFP staining (for Figure S1), HEK cells were plated as above, then infected the following day with serial dilutions of RV $\Delta$ G-4EGFP (Wickersham et al., 2010), RV $\Delta$ GL-4EGFP (Chatterjee et al., 2018), or RV $\Delta L-5 E G F P$, with immunostaining three days postinfection, using a 1:1000 dilution of chicken anti-GFP polyclonal antibody (Aves Labs, GFP-1020) and a 1:500 dilution of Alexa Fluor 594-conjugated donkey anti-chicken secondary antibody (Jackson Immuno 703-585-155).

Immunostained cells on coverslips were mounted on slides using Prolong Diamond Antifade mounting medium (Thermo P36970) and imaged on a Zeiss LSM 900 confocal microscope using a 20x objective.

For matched flow cytometric analysis of immunostained cells, cells were plated in 24 -well plates without poly-L-lysine-coated coverslips but otherwise immunostained as described above, then analyzed on an LSR II flow cytometer (BD) using FACS Diva software (BD). Histograms displayed in Figure 1 were smoothed using the FACS Diva "Smooth histogram" setting.

## Viral growth analysis

For determining growth curves, BHK-B19G3, BHK-B19L-G, and BHK-B19L cells (see above) were plated in 10 cm plates coated in poly-L-lysine in normal medium ( $10 \%$ fetal bovine serum (VWR 16777-014) and antibiotic-antimycotic (Thermo 15240096) in DMEM (Thermo 11995073)) (Wickersham et al., 2010). The following day, cells were infected with RVAG-4Cre(B19G), RV $\Delta \mathrm{GL}-4 \operatorname{Cre}$ (B19G), or RV $\Delta L-5 C r e(B 19 G)$ at an MOI of either 1 (for single-step growth curves) or 0.01 (for multi-step growth curves), with viruses diluted in normal medium at a total volume of 2 ml per plate, with each condition in triplicate. Following a one-hour incubation, the virus-containing medium was aspirated, plates were washed twice in DPBS (Thermo 14190144), and 12 ml fresh medium was added to each plate before they were returned to the incubator. Every 24 hours for the following five days, $200 \mu$ l of supernatant was collected from each plate; these supernatant samples were filter-sterilized using a 96 -well 0.45 um PVDF filter plate (Millipore MSHVN4510), then frozen at $-80^{\circ} \mathrm{C}$ before all samples were thawed and titered on HEK 293T-FLEX-BC cells as described above.

## Mouse strains

The Cre-dependent tdTomato reporter line Ai14 (Madisen et al., 2010) was purchased from Jackson Laboratory (catalog \# 007914). The Flp-dependent tdTomato reporter line Ai65F was obtained by crossing the Cre- and Flp-dependent tdTomato double-reporter line Ai65D (Madisen et al., 2015) (Jackson Laboratory 021875) to the Cre deleter line Meox2-Cre (Tallquist and Soriano, 2000) (Jackson Laboratory 003755), then breeding out the Meox2-Cre alleel. An equivalent Ai65F line, made using a different Cre deleter line, was described in Daigle et al. '18 (Daigle et al., 2018) and is now available from Jackson Laboratory (catalog \# 032864). The tTA-dependent tdTomato reporter line Ai63 (Daigle et al., 2018) was a generous gift from Hongkui Zeng and Tanya Daigle. Mice used for the functional two-photon imaging experiments were crosses of the Cre- and tTA-dependent GCaMP6s line Ai94D (Jackson Laboratory 024104) with the Cre-dependent tTA line ROSA:LNL.:TTA (Wang et al., 2008) (Jackson Laboratory 011008). All mice were maintained in a C57BL/6J (Jackson Laboratory 000664) background.

For experiments, adult mice of both sexes were used, of the following mouse strains. For retrograde targeting using Cre-expressing viruses (Figure 2) and structural two-photon imaging (Figure 3): Ai14 heterozygotes. For retrograde targeting using Flpo-expressing viruses (Figure 2): Ai65F heterozygotes. For retrograde targeting using RVAL-TTA (Figure S3): Ai63 heterozygotes. For functional two-photon imaging (Figures 4, S4, and S5): Ai94D x ROSA:LNL:tTA double homozygotes.

## Stereotaxic injections

200 nl of rabies virus was injected into either somatosensory thalamus (VPM/Po, for figure 2) or primary visual cortex (for two-photon experiments) of anesthetized adult mice using a stereotaxic instrument (Stoelting Co., 51925) and a custom injection apparatus consisting of a hydraulic manipulator (Narishige, MO-10) with headstage coupled via custom adaptors to a wire plunger advanced through pulled glass capillaries (Drummond, Wiretrol II) back-filled with mineral oil and front-filled with viral vector solution (Lavin et al., 2019). We have described this injection system in detail previously. Injection coordinates for VPM/Po were: anteroposterior (AP) $=-1.82 \mathrm{~mm}$ with respect to (w.r.t.) bregma, lateromedial $(\mathrm{LM})=+1.54 \mathrm{~mm}$ w.r.t bregma, dorsoventral (DV) $=-3.15 \mathrm{~mm}$ w.r.t the brain surface; injection coordinates for V 1 cortex were: AP $=-2.70 \mathrm{~mm}$ w.r.t. bregma, $\mathrm{LM}=2.50 \mathrm{~mm}$ w.r.t. bregma, $\mathrm{DV}=-0.26 \mathrm{~mm}$ w.r.t the brain surface .

For mice to be used for two-photon imaging, a 3 mm craniotomy was opened over primary visual cortex (V1). Glass windows composed of a 3mm-diameter glass coverslip (Warner Instruments CS-3R) glued (Optical Adhesive 61, Norland Products) to a 5mm-diameter glass coverslip (Warner Instruments CS-5R) were affixed over the craniotomy with Metabond (Parkell) after virus injection.

For the $\Delta \mathrm{GL}$ vs. $\Delta \mathrm{L}$ experiments (Figure 2), the four viruses were produced in parallel for direct comparison, and RV $\Delta \mathrm{L}-\mathrm{Cre}(6.16 \mathrm{E}+10 \mathrm{i} . \mathrm{u} . / \mathrm{ml})$ or $\mathrm{RV} \Delta \mathrm{GL}-\mathrm{Cre}$ (3.01E+09 i.u./ml) was injected into Ai14
 (het) mice. For the 4 -month and 6 -month experiments for Figure 2, RV $\Delta \mathrm{L}-\mathrm{Cre}(1.66 \mathrm{E}+10$ i.u. $/ \mathrm{ml}$ ) was injected into Ai14 (het) mice. For Figure S3, RV $\Delta \mathrm{L}-\mathrm{tTA}(3.63 \mathrm{E}+10 \mathrm{iu} / \mathrm{ml}$ ) was injected into Ai63 (het) mice.

For two-photon structural experiments (Figure 3), RV $\Delta$ GL-Cre (1.19E $+10 \mathrm{iu} / \mathrm{ml}$ ) or RV $\Delta \mathrm{L}-\mathrm{Cre}$ $(1.66 \mathrm{E}+10 \mathrm{iu} / \mathrm{ml}$ diluted to $1.19 \mathrm{E}+10 \mathrm{iu} / \mathrm{ml}$ for matching to $\mathrm{RV} \Delta \mathrm{GL}-\mathrm{Cre}$ ) was injected into Ai14 (het) mice. For two-photon functional experiments in Figure 4, RV $\Delta L-C r e ~(2.61 \mathrm{E}+10 \mathrm{iu} / \mathrm{ml})$ was injected into homo/homo Ai94D x ROSA:LNL:tTA mice.

## Perfusions, histology, and confocal imaging

1 week to 6 months (see main text) after injection of rabies virus, anesthetized mice were transcardially perfused with $4 \%$ paraformaldehyde. Brains were postfixed overnight in $4 \%$ paraformaldehyde in PBS on a shaker at $4^{\circ} \mathrm{C}$ and cut into $50 \mu \mathrm{~m}$ coronal sections on a vibrating microtome (Leica, VT-1000S). Sections were collected sequentially into 6 tubes containing cryoprotectant, so that each tube contained every sixth section, then frozen at $-20^{\circ} \mathrm{C}$. Sections to be imaged were washed to remove cryoprotectant, then mounted with Prolong Diamond Antifade mounting medium (Thermo Fisher P36970) and imaged on a confocal microscope (Zeiss, LSM 900). To ensure that the confocal images included in the figures are representative of each group, the images were taken after the counts were conducted, and the mouse with the next higher number of labeled neurons than the average number for its group was selected for confocal imaging.

## Quantification of retrograde targeting

Coronal sections between 0.43 mm anterior and 4.07 mm posterior to bregma were imaged with an epifluorescence microscope for cell counting (Zeiss, Imager.Z2). Due to the high density of retrogradely labeled tdTomato neurons in the cortex at the injection site (VPM/Po), cells were counted using the Analyze Particle function in ImageJ (size in micron^2: 20-400; circularity: 0.20-1.00). Only one of the six series of sections (i.e., every sixth section: see above) was counted for each mouse. P-values for all comparisons were obtained using single-factor ANOVAs.

## Structural two-photon imaging and image analysis

Beginning seven days after injection of each rabies virus and recurring at the subsequent indicated timepoints (see main text) up to a maximum of 16 weeks following rabies virus injection, fields of view (FOVs) were imaged on a Prairie/Bruker Ultima IV In Vivo two-photon microscope driven by a Spectra Physics Mai-Tai Deep See laser with a mode locked Ti:sapphire laser emitting at a wavelength of 1020 nm for excitation of tdTomato. In order to distinguish individual labeled neurons, FOVs were chosen some distance away from the area of brightest tdTomato labeling. Two well-separated areas were chosen in each mouse. For each imaging session, mice were reanesthetized and mounted via their headplates to a custom frame, with ointment applied to protect their eyes and with a handwarmer maintaining body temperature. Imaging parameters were as follows: image size $512 \times 512$ pixels ( $282.6 \mu \mathrm{~m} \times 282.6 \mu \mathrm{~m}$ ), 0.782 Hz frame rate, dwell time $4.0 \mu \mathrm{~s}, 2 \mathrm{x}$ optical zoom, Z-stack step size $1 \mu \mathrm{~m}$. Image acquisition was controlled with Prairie View 5.4 software. Laser power exiting the 20x water-immersion objective (Zeiss, W plan-apochromat, NA 1.0) varied between 20 and 65 mW depending on focal plane depth (Pockels cell value was automatically increased from 450 at the top section of each stack to 750 at the bottom section). For the example images of labeled cells, maximum intensity projections (stacks of 100-200 $\mu \mathrm{m}$ ) were made with ImageJ software. Cell counting was automated using the "Analyze Particles" function in ImageJ. Plots of cell counts were made with Prism 9 (GraphPad Software, San Diego, California).

## Functional two-photon imaging and image analysis

For functional two-photon imaging of RV $\Delta \mathrm{L}$-Cre-labeled cells, FOVs were slightly offset from the regions of brightest GCaMP6s label in left-hemisphere V1 in order to allow separate identification of individual cells. This imaging was performed using the same microscope ( $5.356-\mathrm{Hz}$ frame rate, 1024X 128 pixels, 565.1
$\mu \mathrm{m} \times 565.1 \mu \mathrm{~m}$, dwell time $0.8 \mu \mathrm{~s}$, 1x optical zoom, scan angle 45 degree) with the same objective and laser (at 920 nm ) as for the structural imaging experiments. Laser power at the objective ranged from 10 to 65 mW . Calcium imaging data were acquired in supragranular layers (100 to $200 \mu \mathrm{~m}$ deep). Surface vasculature provided coarse fiducial markers for finding the same FOVs in different imaging sessions. For these experiments, mice were awake and head-fixed. No behavioral training or reward was given. Visual stimuli were generated in Matlab (R2015R version) with custom software based on Psychtoolbox (http://psychtoolbox.org) and shown on the same LCD screen as in the widefield mapping experiments. Each condition consisted of 2 s of a full-field sine wave grating drifting in one direction, presented at $80 \%$ contrast with spatial frequency of 0.04 cycles/ degree, followed by 2 s of uniform mean luminance (gray). All permutations of 12 directions ( $30^{\circ}$ steps) and 5 temporal frequencies ( $1,2,4,8$ and 15 Hz ) were shown, in randomized order. The complete set was repeated 10 times, for a total stimulation period of 40 min per FOV per session. Cells were then manually segmented, and single-cell fluorescence traces were extracted by averaging the fluorescence of all pixels masking the soma, using ImageJ (version 2-0-0-rc-69) software. The mean $\Delta F / F$ over the full 2 s of each stimulus condition was used to calculate orientation tuning curves, with background fluorescence (F) in $\Delta F / F$ taken as the value of the trace immediately preceding a condition, averaged over all conditions. The raw calcium traces from cells within individual FOVs (not across FOVs, given different imaging conditions across animals and time points) were sorted by mean fluorescence. Randomly colored ROI view images were created by suite2p (https://www.suite2p.org). For 'tuned' cells in Figure 4 panels $F$ and $G$, the counts are based on all imaged neurons' individual tuning curves, plotted in MATLAB; any cell showing response to a preferred orientation (including narrowly tuned neurons and broadly tuned neurons) at any temporal frequency ( $1 \mathrm{~Hz}, 2 \mathrm{~Hz}, 4 \mathrm{~Hz}, 8 \mathrm{~Hz}$, or 15 Hz ) was counted manually as a tuned cell.

## RESOURCE AVAILABILITY

All cell counts and statistical analyses are provided in Supplemental Information. The novel plasmids described in this paper have been deposited with Addgene with the accession numbers given in Methods.

## SUPPLEMENTAL INFORMATION

Supplemental information can be found online.
A preprint version of this paper is available on bioRxiv.

## ACKNOWLEDGMENTS

We thank Tanya Daigle and Hongkui Zeng for sharing the Ai63 mouse line, Jacque Ip, Chloe Delepine, and Mriganka Sur for sharing mice, Chang Liu for assistance with optimizing MATLAB code for analysis of the functional imaging data, and Sara Beach for helpful suggestions on the manuscript. Research reported in this publication was supported by BRAIN Initiative awards RF1MH120017, U01MH106018, U01MH114829, and U19MH114830 from the National Institute of Mental Health.

## AUTHOR CONTRIBUTIONS

L.J., N.E.L., M.M., Y.H., and M.Z. cloned constructs; H.A.S. produced viruses with assistance from L.J. and M.Z.; H.A.S. conducted cell culture assays and immunocytochemistry; L.J., N.E.L., and T.K.L. performed surgeries; L.J. and M.Z. performed histology and confocal imaging; L.J. performed two-photon imaging; L.J., M.Z., T.K.L., and N.E.L. managed mouse breeding; I.W. planned and supervised all work; I.W. and L.J. wrote the manuscript with input from the other authors.

## DECLARATION OF INTERESTS

I.R.W. is a consultant for Monosynaptix, LLC, advising on design of neuroscientific experiments.

## REFERENCES

Albertini, A.A., Ruigrok, R.W., and Blondel, D. (2011). Rabies virus transcription and replication. Advances in virus research 79, 1-22.
Alitto, H.J., and Usrey, W.M. (2003). Corticothalamic feedback and sensory processing. Curr Opin Neurobiol 13, 440-445.
Bragg, E.M., Fairless, E.A., Liu, S., and Briggs, F. (2017). Morphology of visual sector thalamic reticular neurons in the macaque monkey suggests retinotopically specialized, parallel stream-mixed input to the lateral geniculate nucleus. J Comp Neurol 525, 1273-1290.
Briggs, F., Kiley, C.W., Callaway, E.M., and Usrey, W.M. (2016). Morphological Substrates for Parallel Streams of Corticogeniculate Feedback Originating in Both V1 and V2 of the Macaque Monkey. Neuron 90, 388-399.
Chatterjee, S., Sullivan, H.A., MacLennan, B.J., Xu, R., Hou, Y., Lavin, T.K., Lea, N.E., Michalski, J.E., Babcock, K.R., Dietrich, S., et al. (2018). Nontoxic, double-deletion-mutant rabies viral vectors for retrograde targeting of projection neurons. Nat Neurosci 21, 638-646.
Chen, T.W., Wardill, T.J., Sun, Y., Pulver, S.R., Renninger, S.L., Baohan, A., Schreiter, E.R., Kerr, R.A., Orger, M.B., Jayaraman, V., et al. (2013). Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature 499, 295-300.
Connolly, J.D., Hashemi-Nezhad, M., and Lyon, D.C. (2012). Parallel feedback pathways in visual cortex of cats revealed through a modified rabies virus. J Comp Neurol 520, 988-1004.
Cruz, A.M., Kim, T.H., and Smith, R.J. (2021). Monosynaptic Retrograde Tracing From Prelimbic Neuron Subpopulations Projecting to Either Nucleus Accumbens Core or Rostromedial Tegmental Nucleus. Front Neural Circuits 15, 639733.
Daigle, T.L., Madisen, L., Hage, T.A., Valley, M.T., Knoblich, U., Larsen, R.S., Takeno, M.M., Huang, L., Gu, H., Larsen, R., et al. (2018). A Suite of Transgenic Driver and Reporter Mouse Lines with Enhanced Brain-Cell-Type Targeting and Functionality. Cell 174, 465-480 e422.
Dohaku, R., Yamaguchi, M., Yamamoto, N., Shimizu, T., Osakada, F., and Hibi, M. (2019). Tracing of Afferent Connections in the Zebrafish Cerebellum Using Recombinant Rabies Virus. Front Neural Circuits 13, 30.
Faulkner, R.L., Wall, N.R., Callaway, E.M., and Cline, H.T. (2021). Application of Recombinant Rabies Virus to Xenopus Tadpole Brain. eNeuro.
Finke, S., and Conzelmann, K.K. (2005). Replication strategies of rabies virus. Virus Res.
Foster, N.N., Barry, J., Korobkova, L., Garcia, L., Gao, L., Becerra, M., Sherafat, Y., Peng, B., Li, X., Choi, J.H., et al. (2021). The mouse cortico-basal ganglia-thalamic network. Nature 598, 188-194.

Gallardo, H.F., Tan, C., and Sadelain, M. (1997). The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther 4, 1115-1119.
Gomme, E.A., Faul, E.J., Flomenberg, P., McGettigan, J.P., and Schnell, M.J. (2010). Characterization of a single-cycle rabies virus-based vaccine vector. Journal of virology 84, 2820-2831.
Hasse, J.M., Bragg, E.M., Murphy, A.J., and Briggs, F. (2019). Morphological heterogeneity among corticogeniculate neurons in ferrets: quantification and comparison with a previous report in macaque monkeys. J Comp Neurol 527, 546-557.
Hidaka, Y., Lim, C.K., Takayama-Ito, M., Park, C.H., Kimitsuki, K., Shiwa, N., Inoue, K.I., and Itou, T. (2018). Segmentation of the rabies virus genome. Virus Res 252, 68-75.
Horwitz, J.A., Jenni, S., Harrison, S.C., and Whelan, S.P.J. (2020). Structure of a rabies virus polymerase complex from electron cryo-microscopy. Proc Natl Acad Sci U S A 117, 2099-2107.
Jin, L., Matsuyama, M., Sullivan, H.A., Zhu, M., Lavin, T.K., Hou, Y., Lea, N.E., Pruner, M.T., Ferdínez, M.L.D., and Wickersham, I.R. (2021a). Rabies virus with a destabilization domain added to its nucleoprotein spreads between neurons only if the domain is removed. bioRxiv, 550640.
Jin, L., Sullivan, H.A., Zhu, M., Lavin, T.K., Matsuyama, M., Lea, N.E., Xu, R., Hou, Y., Rutigliani, L., Pruner, M., et al. (2021b). Long-term labeling and imaging of synaptically-connected neuronal networks <em>in vivo</em> using nontoxic, double-deletion-mutant rabies viruses. bioRxiv, 2021.2012.2004.471186.
Koresawa, Y., Miyagawa, S., Ikawa, M., Matsunami, K., Yamada, M., Shirakura, R., and Okabe, M. (2000). Synthesis of a new Cre recombinase gene based on optimal codon usage for mammalian systems. J Biochem 127, 367-372.
Lavin, T.K., Jin, L., and Wickersham, I.R. (2019). Monosynaptic tracing: a step-by-step protocol. J Chem Neuroanat, 101661.

Liu, K., Kim, J., Kim, D.W., Zhang, Y.S., Bao, H., Denaxa, M., Lim, S.A., Kim, E., Liu, C., Wickersham, I.R., et al. (2017). Lhx6-positive GABA-releasing neurons of the zona incerta promote sleep. Nature 548, 582587.

Liu, Y.J., Ehrengruber, M.U., Negwer, M., Shao, H.J., Cetin, A.H., and Lyon, D.C. (2013). Tracing inputs to inhibitory or excitatory neurons of mouse and cat visual cortex with a targeted rabies virus. Curr Biol 23, 1746-1755.
Lyon, D.C., Nassi, J.J., and Callaway, E.M. (2010). A disynaptic relay from superior colliculus to dorsal stream visual cortex in macaque monkey. Neuron 65, 270-279.
Madisen, L., Garner, A.R., Shimaoka, D., Chuong, A.S., Klapoetke, N.C., Li, L., van der Bourg, A., Niino, Y., Egolf, L., Monetti, C., et al. (2015). Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. Neuron 85, 942-958.
Madisen, L., Zwingman, T.A., Sunkin, S.M., Oh, S.W., Zariwala, H.A., Gu, H., Ng, L.L., Palmiter, R.D., Hawrylycz, M.J., Jones, A.R., et al. (2010). A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nature neuroscience 13, 133-140.
Miyamichi, K., Amat, F., Moussavi, F., Wang, C., Wickersham, I., Wall, N.R., Taniguchi, H., Tasic, B., Huang, Z.J., He, Z., et al. (2011). Cortical representations of olfactory input by trans-synaptic tracing. Nature 472, 191-196.
Morin, B., Kranzusch, P.J., Rahmeh, A.A., and Whelan, S.P. (2013). The polymerase of negative-stranded RNA viruses. Current opinion in virology 3, 103-110.
Nakagawa, K., Kobayashi, Y., Ito, N., Suzuki, Y., Okada, K., Makino, M., Goto, H., Takahashi, T., and Sugiyama, M. (2017). Molecular Function Analysis of Rabies Virus RNA Polymerase L Protein by Using an L Gene-Deficient Virus. J Virol 91.
Nassi, J.J., and Callaway, E.M. (2006). Multiple circuits relaying primate parallel visual pathways to the middle temporal area. J Neurosci 26, 12789-12798.
Nassi, J.J., and Callaway, E.M. (2007). Specialized circuits from primary visual cortex to V2 and area MT. Neuron 55, 799-808.
Nassi, J.J., Lyon, D.C., and Callaway, E.M. (2006). The parvocellular LGN provides a robust disynaptic input to the visual motion area MT. Neuron 50, 319-327.
Ogino, T., and Green, T.J. (2019). Transcriptional Control and mRNA Capping by the GDP Polyribonucleotidyltransferase Domain of the Rabies Virus Large Protein. Viruses 11.
Raymond, C.S., and Soriano, P. (2007). High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells. PLoS One 2, e162.
Reardon, T.R., Murray, A.J., Turi, G.F., Wirblich, C., Croce, K.R., Schnell, M.J., Jessell, T.M., and Losonczy, A. (2016). Rabies Virus CVS-N2c(DeltaG) Strain Enhances Retrograde Synaptic Transfer and Neuronal Viability. Neuron 89, 711-724.
Ren, W., Centeno, M.V., Wei, X., Wickersham, I., Martina, M., Apkarian, A.V., and Surmeier, D.J. (2021). Adaptive alterations in the mesoaccumbal network after peripheral nerve injury. Pain 162, 895-906.
Rockland, K.S. (2021). A Closer Look at Corticothalamic "Loops". Front Neural Circuits 15, 632668.
Rouiller, E.M., and Welker, E. (2000). A comparative analysis of the morphology of corticothalamic projections in mammals. Brain Res Bull 53, 727-741.
Roy, D.S., Zhang, Y., Aida, T., Choi, S., Chen, Q., Hou, Y., Lea, N.E., Skaggs, K.M., Quay, J.C., Liew, M., et al. (2021). Anterior thalamic dysfunction underlies cognitive deficits in a subset of neuropsychiatric disease models. Neuron 109, 2590-2603 e2513.
Satou, C., Neve, R.L., Oyibo, H.K., Zmarz, P., Huang, K.-H., Bouldoires, E.A., Mori, T., Higashijima, S.-i., Keller, G.B., and Friedrich, R.W. (2021). A viral toolbox for conditional and transneuronal gene expression in zebrafish. bioRxiv, 2021.2003.2025.436574.
Schwarz, L.A., Miyamichi, K., Gao, X.J., Beier, K.T., Weissbourd, B., DeLoach, K.E., Ren, J., Ibanes, S., Malenka, R.C., Kremer, E.J., et al. (2015). Viral-genetic tracing of the input-output organization of a central noradrenaline circuit. Nature.
Shaner, N.C., Campbell, R.E., Steinbach, P.A., Giepmans, B.N., Palmer, A.E., and Tsien, R.Y. (2004). Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 22, 1567-1572.
Siu, C., Balsor, J., Merlin, S., Federer, F., and Angelucci, A. (2021). A direct interareal feedback-tofeedforward circuit in primate visual cortex. Nat Commun 12, 4911.
Smith, M.L., Asada, N., and Malenka, R.C. (2021). Anterior cingulate inputs to nucleus accumbens control the social transfer of pain and analgesia. Science 371, 153-159.

Stephenson-Jones, M., Yu, K., Ahrens, S., Tucciarone, J.M., van Huijstee, A.N., Mejia, L.A., Penzo, M.A., Tai, L.H., Wilbrecht, L., and Li, B. (2016). A basal ganglia circuit for evaluating action outcomes. Nature 539, 289-293.
Tallquist, M.D., and Soriano, P. (2000). Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function. Genesis 26, 113-115.
Tasic, B., Yao, Z., Graybuck, L.T., Smith, K.A., Nguyen, T.N., Bertagnolli, D., Goldy, J., Garren, E., Economo, M.N., Viswanathan, S., et al. (2018). Shared and distinct transcriptomic cell types across neocortical areas. Nature 563, 72-78.
Te Velthuis, A.J.W., Grimes, J.M., and Fodor, E. (2021). Structural insights into RNA polymerases of negative-sense RNA viruses. Nat Rev Microbiol 19, 303-318.
Wall, N.R., Wickersham, I.R., Cetin, A., De La Parra, M., and Callaway, E.M. (2010). Monosynaptic circuit tracing in vivo through Cre-dependent targeting and complementation of modified rabies virus. P Natl Acad Sci USA.
Wang, G.P., and Bushman, F.D. (2006). A statistical method for comparing viral growth curves. J Virol Methods 135, 118-123.
Wang, L., Sharma, K., Deng, H.X., Siddique, T., Grisotti, G., Liu, E., and Roos, R.P. (2008). Restricted expression of mutant SOD1 in spinal motor neurons and interneurons induces motor neuron pathology. Neurobiol Dis 29, 400-408.
Wickersham, I.R., Finke, S., Conzelmann, K.K., and Callaway, E.M. (2007a). Retrograde neuronal tracing with a deletion-mutant rabies virus. Nature Methods 4, 47-49.
Wickersham, I.R., Lyon, D.C., Barnard, R.J., Mori, T., Finke, S., Conzelmann, K.K., Young, J.A., and Callaway, E.M. (2007b). Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons. Neuron 53, 639-647.
Wickersham, I.R., and Sullivan, H.A. (2015). Rabies viral vectors for monosynaptic tracing and targeted transgene expression in neurons. Cold Spring Harb Protoc 2015, 375-385.
Wickersham, I.R., Sullivan, H.A., and Seung, H.S. (2010). Production of glycoprotein-deleted rabies viruses for monosynaptic tracing and high-level gene expression in neurons. Nature protocols 5, 595-606.
Wu, X., Morishita, W., Beier, K.T., Heifets, B.D., and Malenka, R.C. (2021). 5-HT modulation of a medial septal circuit tunes social memory stability. Nature 599, 96-101.
Yao, S., Wang, Q., Hirokawa, K.E., Ouellette, B., Ahmed, R., Bomben, J., Brouner, K., Casal, L., Caldejon, S., Cho, A., et al. (2021). A whole-brain monosynaptic input connectome to neuron classes in mouse visual cortex. bioRxiv, 2021.2009.2029.459010.
Yarch, J., Federer, F., and Angelucci, A. (2017). Local Circuits of V1 Layer 4B Neurons Projecting to V2 Thick Stripes Define Distinct Cell Classes and Avoid Cytochrome Oxidase Blobs. J Neurosci 37, 422-436.
Zhu, P., Narita, Y., Bundschuh, S.T., Fajardo, O., Scharer, Y.P., Chattopadhyaya, B., Bouldoires, E.A., Stepien, A.E., Deisseroth, K., Arber, S., et al. (2009). Optogenetic Dissection of Neuronal Circuits in Zebrafish using Viral Gene Transfer and the Tet System. Front Neural Circuits 3, 21.

FIGURES


Figure 1. Rabies virus with just the polymerase gene deleted ( $\Delta \mathrm{L}$ ) is phenotypically similar to double-deletion-mutant ( $\Delta \mathrm{GL}$ ) virus but replicates to much higher titers within complementing cells. (A-D) Deletion of just the polymerase gene $L$ reduces transgene expression to levels that are very low but still sufficient to support reporter allele recombination in Cre reporter cells.
(A) Negative controls (uninfected cells). Top: Uninfected HEK 293T cells stained for rabies virus nucleoprotein (green) and for Cre (red). Histograms to right of panels show flow cytometric quantification of baseline fluorescence of uninfected cells in these channels. Bottom: Uninfected reporter cells which express mCherry following Cre recombination. Little signal is seen in these negative controls.
(B) Cells infected with a first-generation ( $\Delta \mathrm{G}$ ) vector expressing Cre. Both Cre and N are expressed at very high levels, and infected Cre reporter cells brightly express mCherry (note that dilutions at which roughly half of cells were infected were chosen for this figure).
(C) Consistent with our previous findings (Chatterjee et al., 2018), expression of both nucleoprotein and Cre from a second-generation ( $\Delta \mathrm{GL}$ ) vector is drastically reduced with respect to the first-generation vector, with expression levels comparable to those seen in negative controls. Despite this, the low Cre levels are still high enough to activate mCherry expression in reporter cells.
(D) A third-generation ( $\Delta \mathrm{L}$ ) vector expresses nucleoprotein and Cre at similarly very low levels, but again Cre expression is nonetheless high enough to successfully activate mCherry expression in reporter cells. (E-F) Third-generation ( $\Delta \mathrm{L}$ ) vectors grow to much high titers in cultured cells than second-generation ( $\Delta \mathrm{GL}$ ) ones do.
(E) Viral titers in supernatants of complementing cells (expressing L, G, or both) infected with $\Delta \mathrm{L}, \Delta \mathrm{GL}$, or $\Delta G$ viruses at a multiplicity of infection (MOI) of 0.01 ("multi-step growth curves"), with supernatants collected every 24 hours for five days. Whereas a $\Delta$ GL virus only achieves $1.05 \mathrm{E}+06$ infectious units (i.u.)/ml over the duration of the experiment, the $\Delta \mathrm{L}$ virus grows to 6.2 -fold higher on the same cell line, and 12.5 -fold higher on a line expressing $L$ alone. The highest $\Delta L$ titers obtained in this experiment were significantly higher than the highest obtained with a first-generation $(\Delta G)$ virus (single-factor ANOVA, $p=$ $3.24 \mathrm{E}-03, \mathrm{n}=3$ replicates per condition).
(F) Similarly, at a MOI of 1 ("single-step" growth curves), the $\Delta \mathrm{GL}$ virus titer peaks at $2.37 \mathrm{E}+06 \mathrm{i} . \mathrm{u} . / \mathrm{ml}$, whereas the peak titer of the $\Delta \mathrm{L}$ virus is $2.60 \mathrm{E}+07 \mathrm{i} . \mathrm{u} . / \mathrm{ml}, 11.0$-fold higher than that of the $\Delta \mathrm{GL}$ virus and not significantly different from that of the $\Delta G$ virus (single-factor ANOVA, $p=0.105, n=3$ replicates per condition). Graphs in (E-F) show means $\pm$ s.e.m.


A


F

G at least six months. $=0.0608, \mathrm{n}=8$ mice per group).

Figure 2. Third-generation ( $\Delta \mathrm{L}$ ) rabies viral vectors retrogradely label many more projection neurons in vivo than do second-generation ( $\Delta \mathrm{GL}$ ) ones and leave cells morphologically normal for
(A) Design of experiments retrogradely targeting corticothalamic cells in reporter mice. Either secondgeneration vector RV $\Delta$ GL-Flpo or $R V \Delta$ GL-Cre, or third-generation vector $R V \Delta L-F l p o$ or $R V \Delta L-C r e$, was injected into somatosensory thalamus (VPM/Po) of either Ai65F (Flpo reporter) or Ai14 (Cre reporter). Mice were perfused 1 week (b, d), 4 weeks (c, e), 4 months (f), or 6 months later ( g ).
(B-E) Efficacy comparison of Flpo- and Cre-expressing $\Delta G L$ and $\Delta L$ vectors.
(B) Corticothalamic neurons in S1 of Ai65F mice labeled with RV $\Delta$ GL-Flpo (left) or RV $\Delta$ L-Flpo (center) at 1 week postinjection. Scale bar: $200 \mu \mathrm{~m}$, applies to both images. Counts of labeled cortical neurons are shown at right (each data point is the total number in one series consisting of every sixth $50 \mu \mathrm{~m}$ section from a given brain - see Methods). The $\Delta \mathrm{L}$ virus labeled 24 times as many cortical neurons than the $\Delta \mathrm{GL}$ virus did, although the difference in this case is not significant due to high variance (single-factor ANOVA, $p$
(C) Corticothalamic neurons in S1 of Ai65F mice labeled with RV $\Delta$ GL-Flpo (left) or RV $\Delta$ L-Flpo (center) at 4 weeks postinjection. Scale bar: $200 \mu \mathrm{~m}$, applies to both images. Counts of labeled cortical neurons are shown at right. The $\Delta \mathrm{L}$ virus labeled 6.25 times as many cortical neurons than the $\Delta \mathrm{GL}$ virus did, an extremely significant difference (single-factor ANOVA, $p=0.000321, n=8$ mice per group).
(D) Corticothalamic neurons in S1 of Ai14 mice labeled with RV $\Delta$ GL-Cre (left) or RV $\Delta \mathrm{L}$-Cre (center) at 1 week postinjection. Scale bar: $200 \mu \mathrm{~m}$, applies to both images. Counts of labeled cortical neurons are
shown at right. The $\Delta \mathrm{L}$ virus labeled 1.4 times as many cortical neurons than the $\Delta \mathrm{GL}$ virus did, a highly significant difference (single-factor ANOVA, $\mathrm{p}=0.00420, \mathrm{n}=8$ mice per group).
(E) Corticothalamic neurons in S1 of Ai14 mice labeled with RV $\Delta$ GL-Cre (left) or RV $\Delta \mathrm{L}$-Cre (center) at 4 weeks postinjection. Scale bar: $200 \mu \mathrm{~m}$, applies to both images. Counts of labeled cortical neurons are shown at right. The $\Delta \mathrm{L}$ virus labeled 1.25 times as many cortical neurons than the $\Delta \mathrm{GL}$ virus did, an extremely significant difference (single-factor ANOVA, $p=0.000738, n=8$ mice each group).
(F) Corticothalamic neurons in S1 of Ai14 mice labeled with RV $\Delta \mathrm{L}-\mathrm{Cre}$ at 4 months postinjection. Cells appear morphologically completely normal, with no blebbing or decomposition of processes. Scale bars: $200 \mu \mathrm{~m}$ (left image) and $2 \mu \mathrm{~m}$ (right image).
(G) Corticothalamic neurons in S1 of Ai14 mice labeled with RV $\Delta \mathrm{L}-\mathrm{Cre}$ at 6 months postinjection. Cells still appear morphologically completely normal. Scale bars: $200 \mu \mathrm{~m}$ (left image) and $2 \mu \mathrm{~m}$ (right image).

A


Ai14 mice
C


D


E


B


F


G



Figure 3. Neurons labeled by $\Delta \mathrm{L}$ rabies virus survive for at least 16 weeks.
(A) Experimental design for longitudinal structural two-photon imaging in vivo. Second-generation ( $\Delta \mathrm{GL}$ ) or third-generation $(\Delta \mathrm{L})$ virus expressing Cre was injected in primary visual cortex of reporter mice, then the injection sites were imaged repeatedly for the following 16 weeks.
(B) Example renderings of the same volume of cortex labeled by RV $\Delta \mathrm{L}-\mathrm{Cre}$ and imaged with a two-photon microscope at two different timepoints, 2 weeks (left) and 10 weeks (right). Every labeled neuron visible at 2 weeks is still present at 10 weeks. Scale bar: $50 \mu \mathrm{~m}$. See also Video S1.
(C) \& (F), Example two-photon images of single fields of view (FOV) of cortex labeled by either the secondgeneration vector RV $\Delta$ GL-Cre (C) or the third-generation vector RV $\Delta L-C r e(F)$, imaged at different timepoints, from 1 week (top left) to 12 weeks (bottom right). All labeled neurons visible at earlier timepoints are still present at later ones, for both viruses. Scale bars: $50 \mu \mathrm{~m}$, apply to all images.
(D) \& (G), Absolute numbers of cells visibly labeled by RV $\Delta$ GL-Cre (D) or RV $\Delta L$-Cre (G) for all structural FOVs in the study, at the 1 -week and 4 -week timepoints. Numbers of visibly labeled cells increased by $56.27 \%$ for $\Delta \mathrm{GL}$ and by $67.77 \%$ for $\Delta \mathrm{L}$, as we found previously for second-generation vectors (Chatterjee et al., 2018)), suggesting accumulation and persistent activity of recombinase on this timescale. These increases were both extremely significant (one-tailed paired t-tests, $p=0.000132$ ( $\Delta \mathrm{GL}$ ) and 0.00001003 $(\Delta L), n=8$ FOVs each virus), but there was no significant difference between the increases seen for the two viruses (two-tailed unpaired t-test, $\mathrm{p}=0.5187, \mathrm{n}=8$ FOVs per group).
(E) \& (H), Percentages of cells visibly labeled by RV $\Delta$ GL-Cre (E) and RV $\Delta L-C r e(H)$ over time, relative to the numbers visible at 1 week after rabies injection; each connected set of dots represents numbers seen in a given FOV at the different time points. For both viruses, the numbers of labeled neurons remain nearly


Figure 4. $\Delta \mathrm{L}$ rabies virus does not appear to perturb neurons' visual response properties for at least 16 weeks.
(A) Experimental design for longitudinal functional two-photon imaging in vivo. $\Delta \mathrm{L}$ virus expressing Cre was injected in primary visual cortex of reporter mice expressing GCaMP6s (Chen et al., 2013) after Cre recombination, then the injection sites were imaged while the awake mice were presented with drifting grating stimuli of different orientations and temporal frequencies, repeatedly for 16 weeks following virus injection.
(B) Example FOV from a GCaMP6s imaging session 16 weeks after RV injection. Individual analyzed cells are randomly pseudocolored. This is the same FOV as shown in Video S2. Scale bar: $50 \mu \mathrm{~m}$.
 top rows show maximum intensity projections of the imaged GCaMP6s signal in two different FOVs at three different timepoints for each FOV. Scale bars: $20 \mu \mathrm{~m}$, apply to all images. Visual response tuning curves of the two circled cells in each FOV at the corresponding timepoint, obtained with drifting gratings presented at 12 directions of motion and 5 temporal frequencies (TF) (mean $\Delta F / F \pm$ s.e.m., averaged over 10 repeats), are shown under each image. More examples from the same FOV are shown in Figure S5.
(E) Single-cell fluorescence time courses for 120 cells at the 12-week timepoint, showing activity over all five temporal frequencies (mean $\Delta F / F$, averaged over 10 repeats). Cells are ranked in descending order of total activity. Scale bar: 10 s .
(F) Percentages of labeled cells that were visually tuned (see Methods), from 6 different FOVs in 3 mice imaged over 14 weeks. Connected sets of dots in a given color indicate data from a single mouse (data from 2 FOVs are shown per mouse).
(G) Comparison of the percentages of labeled cells that were visually tuned at 2 weeks and 14 weeks. The percentages increased moderately but significantly between the two timepoints, from $60 \%$ to $68 \%$ (paired two-sample t-test, $\mathrm{p}=0.0178, \mathrm{n}=6$ ).

## SUPPLEMENTAL INFORMATION



Figure S1. $\Delta \mathrm{L}$ and $\Delta$ GL viruses express EGFP at similarly low levels, Related to Figure 1 Confocal images and flow cytometric histograms showing native and immunostained EGFP signal in uninfected cells $(A)$ and cells infected with first-generation $(\Delta G)$ virus (B), second-generation ( $\Delta G L$ ) virus (C), or third-generation virus (D) expressing EGFP. Scale bar: $50 \mu \mathrm{~m}$, applies to all images.

A Multi-step growth curves (MOI=0.01)


B $\quad$ Single-step growth curves (MOI=1)

Figure S2. $\Delta \mathbf{G}, \Delta \mathbf{G L}$, and $\Delta \mathbf{L}$ viruses do not propagate in non-complementing cells, Related to Figure 1 Viral titers in supernatants of BHK-21 cells not expressing any rabies viral genes, infected with $\Delta \mathrm{L}, \Delta \mathrm{GL}$, or $\Delta \mathrm{G}$ viruses at a multiplicity of infection (MOI) of 0.01 ("multi-step growth curves", panel A) or 1 ("singlestep" growth curves, panel B), with supernatants collected every 24 hours for five days. Graphs show mean $\pm$ s.e.m. .Black lines show negative control "titers" calculated from uninfected reporter cells (mean $\pm$ s.e.m. of 10 samples). Note that the titers in these graphs are 3-4 orders of magnitude lower than those obtained on complementing cells (Figure 1).

File S1. Titers and statistics for growth dynamics experiments, Related to Figure 1
See following pages.
bioRxiv preprint doi: https://doi.org/10.1101/2022.02.23.481706; this version posted April 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.

| FACS data from Single-step growth curves (Infectious units/mL) | 24hr | 48hr | 72hr | 96hr | 120hr |
| :---: | :---: | :---: | :---: | :---: | :---: |
| (1) RVAGL-Cre (on B19L-G_01 cells) | $1.89 \mathrm{E}+05$ | $1.99 \mathrm{E}+06$ | $2.39 \mathrm{E}+06$ | $1.76 \mathrm{E}+06$ | $1.94 \mathrm{E}+06$ |
| (2) RVAGL-Cre (on B19L-G_01 cells) | $1.48 \mathrm{E}+05$ | $1.97 \mathrm{E}+06$ | $2.46 \mathrm{E}+06$ | $1.77 \mathrm{E}+06$ | $1.92 \mathrm{E}+06$ |
| (3) RVAGL-Cre (on B19L-G_01 cells) | $1.55 \mathrm{E}+05$ | $1.89 \mathrm{E}+06$ | $2.25 \mathrm{E}+06$ | $1.55 \mathrm{E}+06$ | $1.73 \mathrm{E}+06$ |
| (7) RVAL-Cre (on B19L_02 cells) | $8.60 \mathrm{E}+05$ | $1.84 \mathrm{E}+07$ | $2.60 \mathrm{E}+07$ | $2.71 \mathrm{E}+07$ | $2.10 \mathrm{E}+07$ |
| (8) RVAL-Cre (on B19L_02 cells) | $7.05 \mathrm{E}+05$ | $1.35 \mathrm{E}+07$ | $2.11 \mathrm{E}+07$ | $2.54 \mathrm{E}+07$ | $1.92 \mathrm{E}+07$ |
| (9) RVAL-Cre (on B19L_02 cells) | $1.17 \mathrm{E}+06$ | $1.65 \mathrm{E}+07$ | $2.25 \mathrm{E}+07$ | $2.56 \mathrm{E}+07$ | $1.70 \mathrm{E}+07$ |
| (13) RVAL-Cre (on B19L-G_01 cells) | $1.31 \mathrm{E}+06$ | $1.92 \mathrm{E}+07$ | $2.02 \mathrm{E}+07$ | $1.87 \mathrm{E}+07$ | $1.79 \mathrm{E}+07$ |
| (14) RVDL-Cre (on B19L-G_01 cells) | $1.88 \mathrm{E}+06$ | $1.96 \mathrm{E}+07$ | $1.92 \mathrm{E}+07$ | $1.67 \mathrm{E}+07$ | $1.79 \mathrm{E}+07$ |
| (15) RVAL-Cre (on B19L-G_01 cells) | $1.61 \mathrm{E}+06$ | $1.89 \mathrm{E}+07$ | $1.94 \mathrm{E}+07$ | $1.51 \mathrm{E}+07$ | $1.70 \mathrm{E}+07$ |
| (19) RVAG-Cre (on B19G3-2 cells) | $2.13 \mathrm{E}+06$ | $3.12 \mathrm{E}+07$ | $3.22 \mathrm{E}+07$ | $3.02 \mathrm{E}+07$ | $2.71 \mathrm{E}+07$ |
| (20) RVAG-Cre (on B19G3-2 cells) | $1.89 \mathrm{E}+06$ | $3.22 \mathrm{E}+07$ | $3.24 \mathrm{E}+07$ | $2.63 \mathrm{E}+07$ | $2.92 \mathrm{E}+07$ |
| (21) RVAG-Cre (on B19G3-2 cells) | $1.39 \mathrm{E}+06$ | $2.19 \mathrm{E}+07$ | $2.64 \mathrm{E}+07$ | $2.01 \mathrm{E}+07$ | $2.35 \mathrm{E}+07$ |
| (25) RVAG-Cre (on B19L-G_01 cells) | $1.71 \mathrm{E}+05$ | $2.04 \mathrm{E}+06$ | $1.14 \mathrm{E}+07$ | $1.36 \mathrm{E}+07$ | $1.37 \mathrm{E}+07$ |
| (26) RVAG-Cre (on B19L-G_01 cells) | $1.84 \mathrm{E}+05$ | $2.40 \mathrm{E}+06$ | $1.09 \mathrm{E}+07$ | $1.18 \mathrm{E}+07$ | $1.36 \mathrm{E}+07$ |
| (27) RVAG-Cre (on B19L-G_01 cells) | $1.65 \mathrm{E}+05$ | $2.01 \mathrm{E}+06$ | $9.61 \mathrm{E}+06$ | $1.02 \mathrm{E}+07$ | $1.14 \mathrm{E}+07$ |
|  |  |  |  |  |  |
| FACS data from Multi-step growth curves (Infectious units/mL) | 24hr | 48hr | 72 hr | 96hr | 120hr |
| (4) RVAGL-Cre (on B19L-G_01 cells) | $6.22 \mathrm{E}+03$ | $4.36 \mathrm{E}+04$ | $5.17 \mathrm{E}+05$ | $7.09 \mathrm{E}+05$ | $1.21 \mathrm{E}+06$ |
| (5) RVAGL-Cre (on B19L-G_01 cells) | 7.77E+03 | $4.39 \mathrm{E}+04$ | $4.47 \mathrm{E}+05$ | $7.78 \mathrm{E}+05$ | $9.81 \mathrm{E}+05$ |
| (6) RVAGL-Cre (on B19L-G_01 cells) | $5.91 \mathrm{E}+03$ | $6.31 \mathrm{E}+04$ | $4.30 \mathrm{E}+05$ | $6.82 \mathrm{E}+05$ | $9.70 \mathrm{E}+05$ |
| (10) RVDL-Cre (on B19L_02 cells) | $6.84 \mathrm{E}+03$ | $5.48 \mathrm{E}+05$ | $5.50 \mathrm{E}+06$ | $9.25 \mathrm{E}+06$ | $1.26 \mathrm{E}+07$ |
| (11) RVAL-Cre (on B19L_02 cells) | $5.28 \mathrm{E}+03$ | $2.96 \mathrm{E}+05$ | $4.67 \mathrm{E}+06$ | $9.18 \mathrm{E}+06$ | $1.34 \mathrm{E}+07$ |
| (12) RVAL-Cre (on B19L_02 cells) | $5.59 \mathrm{E}+03$ | $6.57 \mathrm{E}+05$ | $6.63 \mathrm{E}+06$ | $1.07 \mathrm{E}+07$ | $1.34 \mathrm{E}+07$ |
| (16) RVAL-Cre (on B19L-G_01 cells) | $8.71 \mathrm{E}+03$ | $1.31 \mathrm{E}+06$ | $7.69 \mathrm{E}+06$ | $5.80 \mathrm{E}+06$ | $6.84 \mathrm{E}+06$ |
| (17) RVDL-Cre (on B19L-G_01 cells) | $4.04 \mathrm{E}+03$ | $1.38 \mathrm{E}+06$ | $6.40 \mathrm{E}+06$ | $6.33 \mathrm{E}+06$ | $6.57 \mathrm{E}+06$ |
| (18) RVAL-Cre (on B19L-G_01 cells) | $5.91 \mathrm{E}+03$ | $1.11 \mathrm{E}+06$ | $5.39 \mathrm{E}+06$ | $5.40 \mathrm{E}+06$ | $6.11 \mathrm{E}+06$ |
| (22) RVAG-Cre (on B19G3-2 cells) | $3.31 \mathrm{E}+04$ | $1.70 \mathrm{E}+06$ | $7.96 \mathrm{E}+06$ | $8.63 \mathrm{E}+06$ | $7.39 \mathrm{E}+06$ |
| (23) RVAG-Cre (on B19G3-2 cells) | $2.24 \mathrm{E}+04$ | $6.82 \mathrm{E}+05$ | $4.13 \mathrm{E}+06$ | $5.36 \mathrm{E}+06$ | $4.99 \mathrm{E}+06$ |
| (24) RVAG-Cre (on B19G3-2 cells) | $2.43 \mathrm{E}+04$ | $8.56 \mathrm{E}+05$ | $4.41 \mathrm{E}+06$ | $6.52 \mathrm{E}+06$ | $5.61 \mathrm{E}+06$ |
| (28) RVAG-Cre (on B19L-G_01 cells) | $6.84 \mathrm{E}+03$ | $6.25 \mathrm{E}+04$ | $5.56 \mathrm{E}+05$ | $2.23 \mathrm{E}+06$ | $5.91 \mathrm{E}+06$ |
| (29) RVAG-Cre (on B19L-G_01 cells) | $5.28 \mathrm{E}+03$ | $3.23 \mathrm{E}+04$ | $3.33 \mathrm{E}+05$ | $1.27 \mathrm{E}+06$ | $4.70 \mathrm{E}+06$ |
| (30) RVAG-Cre (on B19L-G_01 cells) | $8.40 \mathrm{E}+03$ | $4.24 \mathrm{E}+04$ | $4.88 \mathrm{E}+05$ | $1.67 \mathrm{E}+06$ | $5.21 \mathrm{E}+06$ |


| Average titers for Single-step growth curves (Infectious units/mL) | 24hr | 48hr | 72hr | 96hr | 120hr |
| :---: | :---: | :---: | :---: | :---: | :---: |
| (1-3) RVAGL-Cre (on B19L-G_01 cells) | $1.64 \mathrm{E}+05$ | $1.95 \mathrm{E}+06$ | $2.37 \mathrm{E}+06$ | $1.69 \mathrm{E}+06$ | $1.86 \mathrm{E}+06$ |
| (7-9) RVAL-Cre (on B19L_02 cells) | $9.12 \mathrm{E}+05$ | $1.61 \mathrm{E}+07$ | $2.32 \mathrm{E}+07$ | $2.60 \mathrm{E}+07$ | $1.91 \mathrm{E}+07$ |
| (13-15) RVAL-Cre (on B19L-G_01 cells) | $1.60 \mathrm{E}+06$ | $1.92 \mathrm{E}+07$ | $1.96 \mathrm{E}+07$ | $1.68 \mathrm{E}+07$ | $1.76 \mathrm{E}+07$ |
| (19-21) RVAG-Cre (on B19G3-2 cells) | $1.81 \mathrm{E}+06$ | $2.85 \mathrm{E}+07$ | $3.03 \mathrm{E}+07$ | $2.55 \mathrm{E}+07$ | $2.66 \mathrm{E}+07$ |
| (25-27) RVAG-Cre (on B19L-G_01 cells) | $1.73 \mathrm{E}+05$ | $2.15 \mathrm{E}+06$ | $1.06 \mathrm{E}+07$ | $1.19 \mathrm{E}+07$ | $1.29 \mathrm{E}+07$ |
| Standard error of the mean for Single-step growth curves (Infectious units/mL) | 24hr | 48hr | 72hr | 96hr | 120hr |
| (1-3) RVAGL-Cre (on B19L-G_01 cells) | $1.27 \mathrm{E}+04$ | $3.12 \mathrm{E}+04$ | $6.11 \mathrm{E}+04$ | $7.25 \mathrm{E}+04$ | $6.73 \mathrm{E}+04$ |
| (7-9) RVAL-Cre (on B19L_02 cells) | $1.37 \mathrm{E}+05$ | $1.42 \mathrm{E}+06$ | $1.45 \mathrm{E}+06$ | $5.43 \mathrm{E}+05$ | $1.16 \mathrm{E}+06$ |
| (13-15) RVAL-Cre (on B19L-G_01 cells) | $1.64 \mathrm{E}+05$ | $2.12 \mathrm{E}+05$ | $3.21 \mathrm{E}+05$ | $1.04 \mathrm{E}+06$ | $3.02 \mathrm{E}+05$ |
| (19-21) RVAG-Cre (on B19G3-2 cells) | $2.18 \mathrm{E}+05$ | $3.29 \mathrm{E}+06$ | $1.99 \mathrm{E}+06$ | $2.94 \mathrm{E}+06$ | $1.66 \mathrm{E}+06$ |
| (25-27) RVAG-Cre (on B19L-G_01 cells) | $5.71 \mathrm{E}+03$ | $1.24 \mathrm{E}+05$ | $5.38 \mathrm{E}+05$ | $9.85 \mathrm{E}+05$ | $7.57 \mathrm{E}+05$ |
|  |  |  |  |  |  |
| Average titers for Multi-step growth curves (Infectious units/mL) | 24hr | 48hr | 72hr | 96hr | 120hr |
| (4-6) RVAGL-Cre (on B19L-G_01 cells) | $6.63 \mathrm{E}+03$ | $5.02 \mathrm{E}+04$ | $4.65 \mathrm{E}+05$ | $7.23 \mathrm{E}+05$ | $1.05 \mathrm{E}+06$ |
| (10-12) RVAL-Cre (on B19L_02 cells) | $5.91 \mathrm{E}+03$ | $5.00 \mathrm{E}+05$ | $5.60 \mathrm{E}+06$ | $9.72 \mathrm{E}+06$ | $1.31 \mathrm{E}+07$ |
| (16-18) RVAL-Cre (on B19L-G_01 cells) | $6.22 \mathrm{E}+03$ | $1.27 \mathrm{E}+06$ | $6.49 \mathrm{E}+06$ | $5.84 \mathrm{E}+06$ | $6.51 \mathrm{E}+06$ |
| (22-24) RVAG-Cre (on B19G3-2 cells) | $2.66 \mathrm{E}+04$ | $1.08 \mathrm{E}+06$ | $5.50 \mathrm{E}+06$ | $6.83 \mathrm{E}+06$ | $6.00 \mathrm{E}+06$ |
| (28-30) RVAG-Cre (on B19L-G_01 cells) | $6.84 \mathrm{E}+03$ | $4.57 \mathrm{E}+04$ | $4.59 \mathrm{E}+05$ | $1.72 \mathrm{E}+06$ | $5.27 \mathrm{E}+06$ |
|  |  |  |  |  |  |
| Standard error of the mean for Multi-step growth curves | 24hr | 48hr | 72hr | 96hr | 120hr |
| (4-6) RVAGL-Cre (on B19L-G_01 cells) | $5.78 \mathrm{E}+02$ | $6.45 \mathrm{E}+03$ | $2.69 \mathrm{E}+04$ | $2.87 \mathrm{E}+04$ | 7.74E+04 |
| (10-12) RVAL-Cre (on B19L_02 cells) | $4.75 \mathrm{E}+02$ | $1.07 \mathrm{E}+05$ | $5.70 \mathrm{E}+05$ | $5.06 \mathrm{E}+05$ | $2.77 \mathrm{E}+05$ |
| (16-18) RVAL-Cre (on B19L-G_01 cells) | $1.36 \mathrm{E}+03$ | $8.07 \mathrm{E}+04$ | $6.63 \mathrm{E}+05$ | $2.71 \mathrm{E}+05$ | $2.13 \mathrm{E}+05$ |
| (22-24) RVAG-Cre (on B19G3-2 cells) | $3.28 \mathrm{E}+03$ | $3.16 \mathrm{E}+05$ | $1.23 \mathrm{E}+06$ | $9.57 \mathrm{E}+05$ | $7.18 \mathrm{E}+05$ |
| (28-30) RVAG-Cre (on B19L-G_01 cells) | $8.98 \mathrm{E}+02$ | $8.87 \mathrm{E}+03$ | $6.60 \mathrm{E}+04$ | $2.80 \mathrm{E}+05$ | $3.51 \mathrm{E}+05$ |


| Conditions with the highest average titers for Single-step growth curves | Infectious units/mL |
| :---: | :---: |
| (1-3) RVAGL-Cre (on B19L-G_01 cells): 72hr | $2.39 \mathrm{E}+06$ |
|  | $2.46 \mathrm{E}+06$ |
| (7-9) RVAL-Cre (on B19L_02 cells): 96hr | $2.25 \mathrm{E}+06$ |
|  | $2.71 \mathrm{E}+07$ |
|  | $2.54 \mathrm{E}+07$ |
| (19-21) RVAG-Cre (on B19G3-2 cells): 72hr | $2.56 \mathrm{E}+07$ |
|  | $3.22 \mathrm{E}+07$ |
|  | $3.24 \mathrm{E}+07$ |


| Conditions with the highest average titers for Multi-step growth curves | Infectious units/mL |
| :---: | :---: |
| (4-6) RVAGL-Cre (on B19L-G_01 cells): 120 hr | $1.21 \mathrm{E}+06$ |
|  | $9.81 \mathrm{E}+05$ |
|  | $9.70 \mathrm{E}+05$ |
|  | $10-12)$ RVAL-Cre (on B19L_02 cells): 120 hr |
|  | $1.26 \mathrm{E}+07$ |
|  | $1.34 \mathrm{E}+07$ |
| (22-24) RVAG-Cre (on B19G3-2 cells): 96hr | $1.34 \mathrm{E}+07$ |
|  | $8.63 \mathrm{E}+06$ |
|  | $5.36 \mathrm{E}+06$ |


| Column1 | Column2 |
| :--- | :---: |
| average "titer" of BC-FLEX cells: |  |
| $3.63 \mathrm{E}+03$ |  |
|  |  |
| Individual |  |
| BC-FLEX negative "titers" |  |
| NEG_01 | $5.28 \mathrm{E}+03$ |
| NEG_03 | $5.91 \mathrm{E}+03$ |
| NEG_04 | $3.11 \mathrm{E}+03$ |
| NEG_05 | $2.80 \mathrm{E}+03$ |
| NEG_06 | $2.17 \mathrm{E}+03$ |

A


4 weeks


B


Figure S3. Retrograde targeting with third-generation ( $\Delta \mathrm{L}$ ) rabies virus expressing the tetracycline transactivator, Related to Figure 2
(A) Corticothalamic neurons retrogradely labeled by a $\Delta L$ virus expressing tTA injected in the somatosensory thalamus of Ai63 reporter mice (Daigle et al., 2018) (tdTomato driven by TRE-tight) 1 week (left image) or 4 weeks (right image) prior to perfusion. Scale bar: $200 \mu \mathrm{~m}$, applies to both images.
(B) Counts of total labeled cortical neurons across every sixth section (see Methods) of each mouse brain. Numbers are not significantly different between the two time points (single factor ANOVA, $p=0.772, n=4$ mice per group).

File S2. Cell counts and statistics for retrograde targeting experiments, Related to Figure 2
See following pages.

| Condition | Mouse number | Section number | Cell counts |
| :---: | :---: | :---: | :---: |
| RVIGL-Flpo: 1 week | 21021505L | 10 | 5 |
| RVAGL-Flpo: 1 week | 21021505L | 11 | 8 |
| RVAGL-Flpo: 1 week | 21021505L | 12 | 9 |
| RVAGL-Flpo: 1 week | 21021505L | total: | 22 |
| RVAGL-Flpo: 1 week | 21021506L | 9 | 5 |
| RVAGL-Flpo: 1 week | 21021506L | 10 | 6 |
| RVAGL-Flpo: 1 week | 21021506L | 11 | 4 |
| RVAGL-Flpo: 1 week | 21021506L | 12 | 3 |
| RVAGL-Flpo: 1 week | 21021506L | total: | 18 |
| RVAGL-Flpo: 1 week | 21021507ப | 5 | 1 |
| RVAGL-Flpo: 1 week | 21021507ப | 6 | 27 |
| RVAGL-Flpo: 1 week | 21021507ப | 7 | 29 |
| RVAGL-Flpo: 1 week | 21021507L | 8 | 25 |
| RVAGL-Flpo: 1 week | 21021507ப | 9 | 20 |
| RVAGL-Flpo: 1 week | 21021507ப | 10 | 10 |
| RVAGL-Flpo: 1 week | 21021507L | 11 | 4 |
| RVAGL-Flpo: 1 week | 21021507ப | 12 | 3 |
| RVAGL-Flpo: 1 week | 21021507 | 13 | 2 |
| RVAGL-Flpo: 1 week | 21021507ப | total: | 121 |
| RVAGL-Flpo: 1 week | 21021508L | 11 | 1 |
| RVAGL-Flpo: 1 week | 21021508L | 15 | 1 |
| RVAGL-Flpo: 1 week | 21021508L | total: | 2 |
| RVAGL-Flpo: 1 week | 21052505L | 9 | 1 |
| RVAGL-Flpo: 1 week | 21052505L | 10 | 5 |
| RVAGL-Flpo: 1 week | 21052505L | 11 | 1 |
| RVAGL-Flpo: 1 week | 21052505L | total: | 7 |
| RVAGL-Flpo: 1 week | 21052506L | 11 | 4 |
| RVAGL-Flpo: 1 week | 21052506L | 12 | 4 |
| RVAGL-Flpo: 1 week | 21052506L | total: | 8 |
| RVAGL-Flpo: 1 week | 21052507L | 6 | 2 |
| RVAGL-Flpo: 1 week | 21052507L | 7 | 20 |
| RVAGL-Flpo: 1 week | 21052507ப | 8 | 45 |
| RVAGL-Flpo: 1 week | 21052507 | 9 | 26 |
| RVIGL-Flpo: 1 week | 21052507ப | 10 | 5 |
| RVAGL-Flpo: 1 week | 21052507ப | total: | 98 |
| RVAGL-Flpo: 1 week | 21052508L | 8 | 1 |
| RVIGL-Flpo: 1 week | 21052508L | 10 | 1 |
| RVAGL-Flpo: 1 week | 21052508L | 11 | 1 |
| RVAGL-Flpo: 1 week | 21052508L | 12 | 1 |
| RVAGL-Flpo: 1 week | 21052508L | 14 | 2 |
| RVAGL-Flpo: 1 week | 21052508L | total: | 6 |
| RVIL-Flpo: 1 week | 21021805L | 1 | 57 |
| RVAL-Flpo: 1 week | 21021805L | 2 | 20 |
| RVDL-Flpo: 1 week | 21021805L | 3 | 11 |
| RVAL-Flpo: 1 week | 21021805L | 4 | 115 |
| RVDL-Flpo: 1 week | 21021805L | 5 | 270 |
| RVDL-Flpo: 1 week | 21021805L | 6 | 399 |
| RVAL-Flpo: 1 week | 21021805L | 7 | 428 |
| RVDL-Flpo: 1 week | 21021805L | 8 | 542 |
| RVDL-Flpo: 1 week | 21021805L | 9 | 416 |
| RVAL-Flpo: 1 week | 21021805L | 10 | 368 |
| RVDL-Flpo: 1 week | 21021805L | 11 | 240 |
| RVAL-Flpo: 1 week | 21021805L | 12 | 106 |
| RVAL-Flpo: 1 week | 21021805L | 13 | 42 |


| RVAL-Flpo: 1 week | 21021805L | 14 | 52 |
| :---: | :---: | :---: | :---: |
| RVAL-Flpo: 1 week | 21021805L | 15 | 27 |
| RVAL-Flpo: 1 week | 21021805L | total: | 3093 |
| RVAL-Flpo: 1 week | 21021806L | 1 | 1 |
| RVAL-Flpo: 1 week | 21021806L | 4 | 5 |
| RVAL-Flpo: 1 week | 21021806L | 5 | 3 |
| RVAL-Flpo: 1 week | 21021806L | 6 | 4 |
| RVAL-Flpo: 1 week | 21021806L | 7 | 16 |
| RVAL-Flpo: 1 week | 21021806L | 8 | 35 |
| RVAL-Flpo: 1 week | 21021806L | 9 | 93 |
| RVAL-Flpo: 1 week | 21021806L | 10 | 74 |
| RVAL-Flpo: 1 week | 21021806L | 11 | 40 |
| RVAL-Flpo: 1 week | 21021806L | 12 | 24 |
| RVAL-Flpo: 1 week | 21021806L | 13 | 11 |
| RVAL-Flpo: 1 week | 21021806L | 14 | 7 |
| RVAL-Flpo: 1 week | 21021806L | 15 | 7 |
| RVAL-Flpo: 1 week | 21021806L | total: | 320 |
| RVAL-Flpo: 1 week | 21021807 | 5 | 1 |
| RVAL-Flpo: 1 week | 21021807ப | 6 | 2 |
| RVAL-Flpo: 1 week | 21021807 | 7 | 6 |
| RVAL-Flpo: 1 week | 21021807ப | 8 | 8 |
| RVAL-Flpo: 1 week | 21021807 | 9 | 35 |
| RVAL-Flpo: 1 week | 21021807 J | 10 | 64 |
| RVAL-Flpo: 1 week | 21021807ப | 11 | 80 |
| RVAL-Flpo: 1 week | 21021807 | 12 | 55 |
| RVAL-Flpo: 1 week | 21021807 | 13 | 34 |
| RVAL-Flpo: 1 week | 21021807ப | 14 | 13 |
| RVAL-Flpo: 1 week | 21021807 | 15 | 13 |
| RVAL-Flpo: 1 week | 21021807ப | total: | 311 |
| RVAL-Flpo: 1 week | 21021808L | 6 | 7 |
| RVAL-Flpo: 1 week | 21021808L | 7 | 13 |
| RVAL-Flpo: 1 week | 21021808L | 8 | 48 |
| RVAL-Flpo: 1 week | 21021808L | 9 | 74 |
| RVAL-Flpo: 1 week | 21021808L | 10 | 57 |
| RVAL-Flpo: 1 week | 21021808L | 11 | 20 |
| RVAL-Flpo: 1 week | 21021808L | 12 | 13 |
| RVAL-Flpo: 1 week | 21021808L | 13 | 13 |
| RVAL-Flpo: 1 week | 21021808L | 14 | 14 |
| RVAL-Flpo: 1 week | 21021808L | 15 | 4 |
| RVAL-Flpo: 1 week | 21021808L | total: | 263 |
| RVAL-Flpo: 1 week | 21052607ப | 4 | 3 |
| RVAL-Flpo: 1 week | 21052607ப | 5 | 2 |
| RVAL-Flpo: 1 week | 21052607ப | 6 | 4 |
| RVAL-Flpo: 1 week | 21052607ப | 7 | 11 |
| RVAL-Flpo: 1 week | 21052607ப | 8 | 10 |
| RVAL-Flpo: 1 week | 21052607ப | 9 | 4 |
| RVAL-Flpo: 1 week | 21052607ப | 11 | 6 |
| RVAL-Flpo: 1 week | 21052607ப | 12 | 7 |
| RVAL-Flpo: 1 week | 21052607ப | total: | 47 |
| RVAL-Flpo: 1 week | 21052608L | 1 | 105 |
| RVAL-Flpo: 1 week | 21052608L | 2 | 116 |
| RVAL-Flpo: 1 week | 21052608L | 3 | 110 |
| RVAL-Flpo: 1 week | 21052608L | 4 | 192 |
| RVAL-Flpo: 1 week | 21052608L | 5 | 395 |
| RVAL-Flpo: 1 week | 21052608L | 6 | 389 |


| RVAL-Flpo: 1 week | 21052608L | 7 | 421 |
| :---: | :---: | :---: | :---: |
| RVAL-Flpo: 1 week | 21052608L | 8 | 340 |
| RVDL-Flpo: 1 week | 21052608L | 9 | 72 |
| RVDL-Flpo: 1 week | 21052608L | 10 | 14 |
| RVDL-Flpo: 1 week | 21052608L | 11 | 5 |
| RVDL-Flpo: 1 week | 21052608L | 12 | 2 |
| RVDL-Flpo: 1 week | 21052608L | total: | 2161 |
| RVAL-Flpo: 1 week | 21060302L | 1 | 8 |
| RVAL-Flpo: 1 week | 21060302L | 2 | 10 |
| RVAL-Flpo: 1 week | 21060302L | 3 | 17 |
| RVDL-Flpo: 1 week | 21060302L | 4 | 24 |
| RVDL-Flpo: 1 week | 21060302L | 5 | 22 |
| RVAL-Flpo: 1 week | 21060302L | 6 | 29 |
| RVDL-Flpo: 1 week | 21060302L | 7 | 34 |
| RVAL-Flpo: 1 week | 21060302L | 8 | 59 |
| RVAL-Flpo: 1 week | 21060302 | 9 | 78 |
| RVAL-Flpo: 1 week | 21060302L | 10 | 46 |
| RVAL-Flpo: 1 week | 21060302L | 11 | 16 |
| RVDL-Flpo: 1 week | 21060302L | 12 | 12 |
| RVDL-Flpo: 1 week | 21060302L | 13 | 6 |
| RVDL-Flpo: 1 week | 21060302L | 14 | 2 |
| RVDL-Flpo: 1 week | 21060302L | 15 | 2 |
| RVDL-Flpo: 1 week | 21060302L | total: | 365 |
| RVAL-Flpo: 1 week | 21060303L | 1 | 7 |
| RVDL-Flpo: 1 week | 21060303L | 2 | 9 |
| RVDL-Flpo: 1 week | 21060303L | 3 | 10 |
| RVAL-Flpo: 1 week | 21060303L | 4 | 16 |
| RVDL-Flpo: 1 week | 21060303L | 5 | 22 |
| RVDL-Flpo: 1 week | 21060303L | 6 | 27 |
| RVAL-Flpo: 1 week | 21060303L | 7 | 25 |
| RVDL-Flpo: 1 week | 21060303L | 8 | 27 |
| RVAL-Flpo: 1 week | 21060303L | 9 | 36 |
| RVAL-Flpo: 1 week | 21060303L | 10 | 30 |
| RVDL-Flpo: 1 week | 21060303L | 11 | 15 |
| RVDL-Flpo: 1 week | 21060303L | 12 | 7 |
| RVDL-Flpo: 1 week | 21060303L | 14 | 6 |
| RVDL-Flpo: 1 week | 21060303L | 15 | 1 |
| RVAL-Flpo: 1 week | 21060303L | total: | 238 |
| RVAGL-Flpo: 4 weeks | 21021501L | 7 | 2 |
| RVAGL-Flpo: 4 weeks | 21021501LJ | 8 | 12 |
| RVAGL-Flpo: 4 weeks | 21021501LJ | 9 | 25 |
| RVAGL-Flpo: 4 weeks | 21021501L | 10 | 26 |
| RVAGL-Flpo: 4 weeks | 21021501L | 11 | 7 |
| RVAGL-Flpo: 4 weeks | 21021501L | 12 | 3 |
| RVAGL-Flpo: 4 weeks | 21021501L | 13 | 3 |
| RVAGL-Flpo: 4 weeks | 21021501L | 14 | 1 |
| RVAGL-Flpo: 4 weeks | 21021501L | 15 | 1 |
| RVAGL-Flpo: 4 weeks | 21021501L | total: | 80 |
| RVAGL-Flpo: 4 weeks | 21021502 $\downarrow$ | 9 | 2 |
| RVAGL-Flpo: 4 weeks | 21021502 J | 10 | 25 |
| RVAGL-Flpo: 4 weeks | 21021502L | 11 | 26 |
| RVAGL-Flpo: 4 weeks | 21021502L | 12 | 5 |
| RVAGL-Flpo: 4 weeks | 21021502 $Ј$ | 13 | 4 |
| RVAGL-Flpo: 4 weeks | 21021502L | total: | 62 |
| RVAGL-Flpo: 4 weeks | 21021503L | 1 | 88 |


| RVAGL-Flpo: 4 weeks | 21021503L | 2 | 129 |
| :---: | :---: | :---: | :---: |
| RVAGL-Flpo: 4 weeks | 21021503L | 3 | 199 |
| RVAGL-Flpo: 4 weeks | 21021503L | 4 | 254 |
| RVAGL-Flpo: 4 weeks | 21021503L | 5 | 312 |
| RVAGL-Flpo: 4 weeks | 21021503L | 6 | 396 |
| RVAGL-Flpo: 4 weeks | 21021503L | 7 | 351 |
| RVAGL-Flpo: 4 weeks | 21021503L | 8 | 391 |
| RVAGL-Flpo: 4 weeks | 21021503L | 9 | 359 |
| RVAGL-Flpo: 4 weeks | 21021503L | 10 | 295 |
| RVAGL-Flpo: 4 weeks | 21021503L | 11 | 133 |
| RVAGL-Flpo: 4 weeks | 21021503L | 12 | 216 |
| RVAGL-Flpo: 4 weeks | 21021503L | 13 | 59 |
| RVAGL-Flpo: 4 weeks | 21021503L | 14 | 40 |
| RVAGL-Flpo: 4 weeks | 21021503L | 15 | 32 |
| RVAGL-Flpo: 4 weeks | 21021503L | total: | 3254 |
| RVAGL-Flpo: 4 weeks | 21021504 ${ }^{\text {J }}$ | 3 | 1 |
| RVAGL-Flpo: 4 weeks | 21021504 J | 4 | 4 |
| RVAGL-Flpo: 4 weeks | 21021504L | 5 | 22 |
| RVAGL-Flpo: 4 weeks | 21021504 J | 6 | 24 |
| RVAGL-Flpo: 4 weeks | 21021504 J | 7 | 56 |
| RVAGL-Flpo: 4 weeks | 21021504 J | 8 | 78 |
| RVAGL-Flpo: 4 weeks | 21021504 J | 9 | 32 |
| RVAGL-Flpo: 4 weeks | 21021504 J | 10 | 18 |
| RVAGL-Flpo: 4 weeks | 21021504 ${ }^{\text {d }}$ | 11 | 1 |
| RVAGL-Flpo: 4 weeks | 21021504 J | 12 | 1 |
| RVAGL-Flpo: 4 weeks | 21021504L | total: | 237 |
| RVAGL-Flpo: 4 weeks | 21052501L | 2 | 1 |
| RVAGL-Flpo: 4 weeks | 21052501L | 4 | 1 |
| RVAGL-Flpo: 4 weeks | 21052501L | 7 | 2 |
| RVAGL-Flpo: 4 weeks | 21052501L | 8 | 6 |
| RVAGL-Flpo: 4 weeks | 21052501L | 9 | 9 |
| RVDGL-Flpo: 4 weeks | 21052501L | 10 | 9 |
| RVAGL-Flpo: 4 weeks | 21052501L | 11 | 2 |
| RVAGL-Flpo: 4 weeks | 21052501L | 12 | 6 |
| RVAGL-Flpo: 4 weeks | 21052501L | 13 | 4 |
| RVAGL-Flpo: 4 weeks | 21052501L | 14 | 1 |
| RVAGL-Flpo: 4 weeks | 21052501L | 15 | 2 |
| RVAGL-Flpo: 4 weeks | 21052501L | total: | 43 |
| RVAGL-Flpo: 4 weeks | 21052502 J | 6 | 2 |
| RVAGL-Flpo: 4 weeks | 21052502L | 7 | 1 |
| RVAGL-Flpo: 4 weeks | 21052502L | 8 | 4 |
| RVAGL-Flpo: 4 weeks | 21052502 J | 11 | 1 |
| RVAGL-Flpo: 4 weeks | 21052502 J | 14 | 3 |
| RVAGL-Flpo: 4 weeks | 21052502 J | 15 | 3 |
| RVAGL-Flpo: 4 weeks | 21052502 J | total: | 14 |
| RVAGL-Flpo: 4 weeks | 21052503L | 6 | 2 |
| RVAGL-Flpo: 4 weeks | 21052503L | 8 | 1 |
| RVAGL-Flpo: 4 weeks | 21052503L | 9 | 9 |
| RVAGL-Flpo: 4 weeks | 21052503L | 10 | 45 |
| RVAGL-Flpo: 4 weeks | 21052503L | 11 | 33 |
| RVAGL-Flpo: 4 weeks | 21052503L | 12 | 17 |
| RVAGL-Flpo: 4 weeks | 21052503L | 13 | 10 |
| RVAGL-Flpo: 4 weeks | 21052503L | 14 | 7 |
| RVAGL-Flpo: 4 weeks | 21052503L | 15 | 6 |
| RVAGL-Flpo: 4 weeks | 21052503L | total: | 130 |


| RVAGL-Flpo: 4 weeks | 21052504L | 7 | 2 |
| :---: | :---: | :---: | :---: |
| RVAGL-Flpo: 4 weeks | 21052504L | 8 | 13 |
| RVAGL-Flpo: 4 weeks | 21052504L | 9 | 18 |
| RVAGL-Flpo: 4 weeks | 21052504L | 10 | 16 |
| RVAGL-Flpo: 4 weeks | 21052504L | 11 | 8 |
| RVAGL-Flpo: 4 weeks | 21052504L | 12 | 3 |
| RVAGL-Flpo: 4 weeks | 21052504L | 13 | 3 |
| RVAGL-Flpo: 4 weeks | 21052504L | 14 | 1 |
| RVAGL-Flpo: 4 weeks | 21052504L | 15 | 1 |
| RVAGL-Flpo: 4 weeks | 21052504LJ | total: | 65 |
| RVAL-Flpo: 4 weeks | 21021801L | 1 | 36 |
| RVAL-Flpo: 4 weeks | 21021801L | 2 | 18 |
| RVAL-Flpo: 4 weeks | 21021801L | 3 | 2 |
| RVAL-Flpo: 4 weeks | 21021801L | 4 | 28 |
| RVAL-Flpo: 4 weeks | 21021801L | 5 | 180 |
| RVAL-Flpo: 4 weeks | 21021801L | 6 | 415 |
| RVAL-Flpo: 4 weeks | 21021801L | 7 | 622 |
| RVAL-Flpo: 4 weeks | 21021801L | 8 | 649 |
| RVAL-Flpo: 4 weeks | 21021801L | 9 | 739 |
| RVAL-Flpo: 4 weeks | 21021801L | 10 | 577 |
| RVAL-Flpo: 4 weeks | 21021801L | 11 | 431 |
| RVAL-Flpo: 4 weeks | 21021801L | 12 | 211 |
| RVAL-Flpo: 4 weeks | 21021801L | 13 | 166 |
| RVAL-Flpo: 4 weeks | 21021801L | 14 | 170 |
| RVAL-Flpo: 4 weeks | 21021801L | 15 | 370 |
| RVAL-Flpo: 4 weeks | 21021801L | total: | 4614 |
| RVAL-Flpo: 4 weeks | 21021802 $Ј$ | 1 | 3 |
| RVAL-Flpo: 4 weeks | 21021802 J | 2 | 6 |
| RVAL-Flpo: 4 weeks | 21021802 $Ј$ | 3 | 8 |
| RVAL-Flpo: 4 weeks | 21021802 $Ј$ | 5 | 32 |
| RVAL-Flpo: 4 weeks | 21021802 J | 6 | 224 |
| RVAL-Flpo: 4 weeks | 21021802 J | 7 | 279 |
| RVAL-Flpo: 4 weeks | 21021802 $Ј$ | 8 | 287 |
| RVAL-Flpo: 4 weeks | 21021802 J | 9 | 457 |
| RVAL-Flpo: 4 weeks | 21021802 $Ј$ | 10 | 501 |
| RVAL-Flpo: 4 weeks | 21021802 J | 11 | 491 |
| RVAL-Flpo: 4 weeks | 21021802 | 12 | 211 |
| RVAL-Flpo: 4 weeks | 21021802 $Ј$ | 13 | 287 |
| RVAL-Flpo: 4 weeks | 21021802 J | 14 | 220 |
| RVAL-Flpo: 4 weeks | 21021802 J | total: | 3006 |
| RVAL-Flpo: 4 weeks | 21021803L | 2 | 6 |
| RVAL-Flpo: 4 weeks | 21021803L | 3 | 9 |
| RVAL-Flpo: 4 weeks | 21021803L | 4 | 48 |
| RVAL-Flpo: 4 weeks | 21021803L | 5 | 177 |
| RVAL-Flpo: 4 weeks | 21021803L | 6 | 247 |
| RVAL-Flpo: 4 weeks | 21021803L | 7 | 339 |
| RVAL-Flpo: 4 weeks | 21021803L | 8 | 316 |
| RVAL-Flpo: 4 weeks | 21021803L | 9 | 322 |
| RVAL-Flpo: 4 weeks | 21021803L | 10 | 205 |
| RVAL-Flpo: 4 weeks | 21021803LJ | 11 | 78 |
| RVAL-Flpo: 4 weeks | 21021803L | 12 | 46 |
| RVAL-Flpo: 4 weeks | 21021803L | 13 | 41 |
| RVAL-Flpo: 4 weeks | 21021803L | 14 | 13 |
| RVAL-Flpo: 4 weeks | 21021803L | total: | 1847 |
| RVAL-Flpo: 4 weeks | 21021804 ${ }^{\text {J }}$ | 1 | 6 |


| RVAL-Flpo: 4 weeks | 21021804 J | 2 | 14 |
| :---: | :---: | :---: | :---: |
| RVAL-Flpo: 4 weeks | 21021804 ${ }^{\text {J }}$ | 3 | 2 |
| RVAL-Flpo: 4 weeks | 21021804 5 | 4 | 57 |
| RVAL-Flpo: 4 weeks | 21021804 J | 5 | 359 |
| RVAL-Flpo: 4 weeks | 21021804 J | 6 | 414 |
| RVAL-Flpo: 4 weeks | 21021804 J | 7 | 469 |
| RVAL-Flpo: 4 weeks | 21021804 ${ }^{\text {J }}$ | 8 | 576 |
| RVAL-Flpo: 4 weeks | 21021804 J | 9 | 533 |
| RVAL-Flpo: 4 weeks | 21021804 J | 10 | 383 |
| RVAL-Flpo: 4 weeks | 21021804 $\sqrt{\text { d }}$ | 11 | 283 |
| RVAL-Flpo: 4 weeks | 21021804 J | 12 | 114 |
| RVAL-Flpo: 4 weeks | 21021804 J | 13 | 34 |
| RVAL-Flpo: 4 weeks | 21021804 J | 14 | 87 |
| RVAL-Flpo: 4 weeks | 21021804 J | total: | 3331 |
| RVAL-Flpo: 4 weeks | 21052601L | 2 | 1 |
| RVAL-Flpo: 4 weeks | 21052601L | 3 | 1 |
| RVAL-Flpo: 4 weeks | 21052601L | 5 | 16 |
| RVAL-Flpo: 4 weeks | 21052601L | 6 | 10 |
| RVAL-Flpo: 4 weeks | 21052601L | 7 | 28 |
| RVAL-Flpo: 4 weeks | 21052601L | 8 | 92 |
| RVAL-Flpo: 4 weeks | 21052601L | 9 | 161 |
| RVAL-Flpo: 4 weeks | 21052601L | 10 | 232 |
| RVAL-Flpo: 4 weeks | 21052601L | 11 | 280 |
| RVAL-Flpo: 4 weeks | 21052601L | 12 | 201 |
| RVAL-Flpo: 4 weeks | 21052601L | 13 | 143 |
| RVAL-Flpo: 4 weeks | 21052601L | 14 | 106 |
| RVAL-Flpo: 4 weeks | 21052601L | 15 | 98 |
| RVAL-Flpo: 4 weeks | 21052601L | total: | 1369 |
| RVAL-Flpo: 4 weeks | 21052602 J | 1 | 49 |
| RVAL-Flpo: 4 weeks | 21052602L | 2 | 12 |
| RVAL-Flpo: 4 weeks | 21052602 J | 3 | 17 |
| RVAL-Flpo: 4 weeks | 21052602 J | 4 | 51 |
| RVAL-Flpo: 4 weeks | 21052602 J | 5 | 163 |
| RVAL-Flpo: 4 weeks | 21052602 J | 6 | 418 |
| RVAL-Flpo: 4 weeks | 21052602 J | 7 | 489 |
| RVAL-Flpo: 4 weeks | 21052602 J | 8 | 526 |
| RVAL-Flpo: 4 weeks | 21052602L | 9 | 510 |
| RVAL-Flpo: 4 weeks | 21052602 J | 10 | 319 |
| RVAL-Flpo: 4 weeks | 21052602 J | 11 | 179 |
| RVAL-Flpo: 4 weeks | 21052602L | 12 | 72 |
| RVAL-Flpo: 4 weeks | 21052602L | 13 | 48 |
| RVAL-Flpo: 4 weeks | 21052602 J | 14 | 32 |
| RVAL-Flpo: 4 weeks | 21052602 J | 15 | 34 |
| RVAL-Flpo: 4 weeks | 21052602 J | total: | 2919 |
| RVAL-Flpo: 4 weeks | 21052603L | 1 | 38 |
| RVAL-Flpo: 4 weeks | 21052603L | 2 | 33 |
| RVAL-Flpo: 4 weeks | 21052603L | 3 | 16 |
| RVAL-Flpo: 4 weeks | 21052603L | 4 | 44 |
| RVAL-Flpo: 4 weeks | 21052603L | 5 | 302 |
| RVAL-Flpo: 4 weeks | 21052603L | 6 | 648 |
| RVAL-Flpo: 4 weeks | 21052603L | 7 | 636 |
| RVAL-Flpo: 4 weeks | 21052603L | 8 | 666 |
| RVAL-Flpo: 4 weeks | 21052603L | 9 | 582 |
| RVAL-Flpo: 4 weeks | 21052603L | 10 | 409 |
| RVAL-Flpo: 4 weeks | 21052603L | 11 | 207 |


| RVAL-Flpo: 4 weeks | 21052603L | 12 | 79 |
| :---: | :---: | :---: | :---: |
| RVAL-Flpo: 4 weeks | 21052603L | 13 | 26 |
| RVAL-Flpo: 4 weeks | 21052603L | 14 | 25 |
| RVAL-Flpo: 4 weeks | 21052603L | 15 | 19 |
| RVAL-Flpo: 4 weeks | 21052603L | total: | 3730 |
| RVAL-Flpo: 4 weeks | 21052606L | 1 | 43 |
| RVAL-Flpo: 4 weeks | 21052606L | 2 | 23 |
| RVAL-Flpo: 4 weeks | 21052606L | 3 | 14 |
| RVAL-Flpo: 4 weeks | 21052606L | 4 | 32 |
| RVAL-Flpo: 4 weeks | 21052606L | 5 | 220 |
| RVAL-Flpo: 4 weeks | 21052606L | 6 | 503 |
| RVAL-Flpo: 4 weeks | 21052606L | 7 | 616 |
| RVAL-Flpo: 4 weeks | 21052606L | 8 | 622 |
| RVAL-Flpo: 4 weeks | 21052606L | 9 | 560 |
| RVAL-Flpo: 4 weeks | 21052606L | 10 | 403 |
| RVAL-Flpo: 4 weeks | 21052606L | 11 | 179 |
| RVAL-Flpo: 4 weeks | 21052606L | 12 | 82 |
| RVAL-Flpo: 4 weeks | 21052606L | 13 | 56 |
| RVAL-Flpo: 4 weeks | 21052606L | 14 | 68 |
| RVAL-Flpo: 4 weeks | 21052606L | 15 | 33 |
| RVAL-Flpo: 4 weeks | 21052606L | total: | 3454 |
| RVAGL-Cre: 1 week | 21021703L | 1 | 422 |
| RVAGL-Cre: 1 week | 21021703L | 2 | 395 |
| RVAGL-Cre: 1 week | 21021703L | 3 | 606 |
| RVAGL-Cre: 1 week | 21021703L | 4 | 543 |
| RVAGL-Cre: 1 week | 21021703L | 5 | 637 |
| RVAGL-Cre: 1 week | 21021703L | 6 | 848 |
| RVAGL-Cre: 1 week | 21021703L | 7 | 1145 |
| RVAGL-Cre: 1 week | 21021703L | 8 | 1183 |
| RVAGL-Cre: 1 week | 21021703L | 9 | 1292 |
| RVAGL-Cre: 1 week | 21021703L | 10 | 1311 |
| RVAGL-Cre: 1 week | 21021703L | 11 | 1377 |
| RVAGL-Cre: 1 week | 21021703L | 12 | 1251 |
| RVAGL-Cre: 1 week | 21021703L | 13 | 998 |
| RVAGL-Cre: 1 week | 21021703L | 14 | 835 |
| RVAGL-Cre: 1 week | 21021703L | 15 | 641 |
| RVAGL-Cre: 1 week | 21021703L | total: | 13484 |
| RVAGL-Cre: 1 week | 21021704L | 1 | 918 |
| RVAGL-Cre: 1 week | 21021704L | 2 | 975 |
| RVAGL-Cre: 1 week | 21021704L | 3 | 1144 |
| RVAGL-Cre: 1 week | 21021704L | 4 | 1404 |
| RVAGL-Cre: 1 week | 21021704L | 5 | 1491 |
| RVAGL-Cre: 1 week | 21021704L | 6 | 1377 |
| RVAGL-Cre: 1 week | 21021704 J | 7 | 1231 |
| RVAGL-Cre: 1 week | 21021704L | 8 | 1337 |
| RVAGL-Cre: 1 week | 21021704 J | 9 | 1135 |
| RVAGL-Cre: 1 week | 21021704L | 10 | 1058 |
| RVAGL-Cre: 1 week | 21021704 | 11 | 711 |
| RVAGL-Cre: 1 week | 21021704 | 12 | 568 |
| RVAGL-Cre: 1 week | 21021704 J | 13 | 443 |
| RVAGL-Cre: 1 week | 21021704L | 14 | 432 |
| RVAGL-Cre: 1 week | 21021704L | 15 | 411 |
| RVAGL-Cre: 1 week | 21021704L | total: | 14635 |
| RVAGL-Cre: 1 week | 21021707ப | 1 | 497 |
| RVAGL-Cre: 1 week | 21021707ப | 2 | 568 |


| RVAGL-Cre: 1 week | 21021707】 | 3 | 454 |
| :---: | :---: | :---: | :---: |
| RVAGL-Cre: 1 week | 21021707ப | 4 | 454 |
| RVAGL-Cre: 1 week | 21021707ப | 5 | 583 |
| RVAGL-Cre: 1 week | 21021707ப | 6 | 873 |
| RVAGL-Cre: 1 week | 21021707ப | 7 | 973 |
| RVAGL-Cre: 1 week | 21021707ப | 8 | 1133 |
| RVAGL-Cre: 1 week | 21021707ப | 9 | 1220 |
| RVAGL-Cre: 1 week | 21021707ப | 10 | 1176 |
| RVAGL-Cre: 1 week | 21021707ப | 11 | 994 |
| RVAGL-Cre: 1 week | 21021707ப | 12 | 645 |
| RVAGL-Cre: 1 week | 21021707ப | 13 | 467 |
| RVAGL-Cre: 1 week | 21021707ப | 14 | 330 |
| RVAGL-Cre: 1 week | 21021707ப | 15 | 280 |
| RVAGL-Cre: 1 week | 21021707ப | total: | 10647 |
| RVAGL-Cre: 1 week | 21021708L | 1 | 271 |
| RVAGL-Cre: 1 week | 21021708L | 2 | 303 |
| RVAGL-Cre: 1 week | 21021708L | 3 | 386 |
| RVAGL-Cre: 1 week | 21021708L | 4 | 634 |
| RVAGL-Cre: 1 week | 21021708L | 5 | 805 |
| RVAGL-Cre: 1 week | 21021708L | 6 | 931 |
| RVAGL-Cre: 1 week | 21021708L | 7 | 1029 |
| RVAGL-Cre: 1 week | 21021708L | 8 | 1186 |
| RVAGL-Cre: 1 week | 21021708L | 9 | 1227 |
| RVAGL-Cre: 1 week | 21021708L | 10 | 1102 |
| RVAGL-Cre: 1 week | 21021708L | 11 | 1019 |
| RVAGL-Cre: 1 week | 21021708L | 12 | 666 |
| RVAGL-Cre: 1 week | 21021708L | 13 | 431 |
| RVAGL-Cre: 1 week | 21021708L | 14 | 369 |
| RVAGL-Cre: 1 week | 21021708L | 15 | 486 |
| RVAGL-Cre: 1 week | 21021708L | total: | 10845 |
| RVDL-Cre: 1 week | 21021905L | 1 | 1161 |
| RVDL-Cre: 1 week | 21021905L | 2 | 1093 |
| RVDL-Cre: 1 week | 21021905L | 3 | 1072 |
| RVDL-Cre: 1 week | 21021905L | 4 | 1079 |
| RVDL-Cre: 1 week | 21021905L | 5 | 1318 |
| RVIL-Cre: 1 week | 21021905L | 6 | 1417 |
| RVDL-Cre: 1 week | 21021905L | 7 | 1541 |
| RVDL-Cre: 1 week | 21021905L | 8 | 1510 |
| RVIL-Cre: 1 week | 21021905L | 9 | 1500 |
| RVDL-Cre: 1 week | 21021905L | 10 | 1549 |
| RVDL-Cre: 1 week | 21021905L | 11 | 1381 |
| RVDL-Cre: 1 week | 21021905L | 12 | 1109 |
| RVDL-Cre: 1 week | 21021905L | 13 | 532 |
| RVDL-Cre: 1 week | 21021905L | 14 | 380 |
| RVDL-Cre: 1 week | 21021905L | 15 | 265 |
| RVDL-Cre: 1 week | 21021905L | total: | 16907 |
| RVDL-Cre: 1 week | 21021906L | 1 | 985 |
| RVDL-Cre: 1 week | 21021906L | 2 | 1012 |
| RVDL-Cre: 1 week | 21021906L | 3 | 1020 |
| RVDL-Cre: 1 week | 21021906L | 4 | 1060 |
| RVDL-Cre: 1 week | 21021906L | 5 | 1082 |
| RVDL-Cre: 1 week | 21021906L | 6 | 1515 |
| RVDL-Cre: 1 week | 21021906 | 7 | 1808 |
| RVAL-Cre: 1 week | 21021906L | 8 | 1675 |
| RVDL-Cre: 1 week | 21021906L | 9 | 1538 |


| RVAL-Cre: 1 week | 21021906 $\sqrt{\text { J }}$ | 10 | 1728 |
| :---: | :---: | :---: | :---: |
| RVDL-Cre: 1 week | 21021906L | 11 | 955 |
| RVDL-Cre: 1 week | 21021906L | 12 | 1018 |
| RVDL-Cre: 1 week | 21021906L | 13 | 993 |
| RVDL-Cre: 1 week | 21021906L | 14 | 701 |
| RVDL-Cre: 1 week | 21021906L | 15 | 483 |
| RVDL-Cre: 1 week | 21021906L | 16 | 350 |
| RVDL-Cre: 1 week | 21021906L | total: | 17923 |
| RVDL-Cre: 1 week | 21021907ப | 1 | 1207 |
| RVDL-Cre: 1 week | 21021907ப | 2 | 1083 |
| RVDL-Cre: 1 week | 21021907ப | 3 | 1152 |
| RVDL-Cre: 1 week | 21021907ப | 4 | 1225 |
| RVDL-Cre: 1 week | 21021907ப | 5 | 1336 |
| RVDL-Cre: 1 week | 21021907ப | 6 | 1558 |
| RVDL-Cre: 1 week | 21021907ப | 7 | 1498 |
| RVDL-Cre: 1 week | 21021907ப | 8 | 1709 |
| RVDL-Cre: 1 week | 21021907ப | 9 | 1547 |
| RVDL-Cre: 1 week | 21021907ப | 10 | 1718 |
| RVDL-Cre: 1 week | 21021907ப | 11 | 1503 |
| RVDL-Cre: 1 week | 21021907 ل | 12 | 1249 |
| RVDL-Cre: 1 week | 21021907ப | 13 | 845 |
| RVDL-Cre: 1 week | 21021907ப | 14 | 626 |
| RVDL-Cre: 1 week | 21021907ப | 15 | 495 |
| RVDL-Cre: 1 week | 21021907ப | total: | 18751 |
| RVIL-Cre: 1 week | 21021908L | 1 | 1011 |
| RVDL-Cre: 1 week | 21021908L | 2 | 892 |
| RVDL-Cre: 1 week | 21021908L | 3 | 896 |
| RVDL-Cre: 1 week | 21021908L | 4 | 957 |
| RVDL-Cre: 1 week | 21021908L | 5 | 1243 |
| RVDL-Cre: 1 week | 21021908L | 6 | 1448 |
| RVDL-Cre: 1 week | 21021908L | 7 | 1568 |
| RVDL-Cre: 1 week | 21021908L | 8 | 1459 |
| RVDL-Cre: 1 week | 21021908L | 9 | 1573 |
| RVDL-Cre: 1 week | 21021908L | 10 | 1313 |
| RVDL-Cre: 1 week | 21021908L | 11 | 1146 |
| RVDL-Cre: 1 week | 21021908L | 12 | 1046 |
| RVAL-Cre: 1 week | 21021908L | 13 | 774 |
| RVDL-Cre: 1 week | 21021908L | 14 | 483 |
| RVDL-Cre: 1 week | 21021908L | 15 | 448 |
| RVDL-Cre: 1 week | 21021908L | total: | 16257 |
| RVIGL-Cre: 4 weeks | 21021701L | 1 | 1314 |
| RVAGL-Cre: 4 weeks | 21021701L | 2 | 1246 |
| RVIGL-Cre: 4 weeks | 21021701L | 3 | 1351 |
| RVIGL-Cre: 4 weeks | 21021701L | 4 | 1601 |
| RVIGL-Cre: 4 weeks | 21021701L | 5 | 1668 |
| RVIGL-Cre: 4 weeks | 21021701L | 6 | 1618 |
| RVIGL-Cre: 4 weeks | 21021701L | 7 | 1593 |
| RVIGL-Cre: 4 weeks | 21021701L | 8 | 1757 |
| RVIGL-Cre: 4 weeks | 21021701L | 9 | 1730 |
| RVAGL-Cre: 4 weeks | 21021701L | 10 | 1600 |
| RVIGL-Cre: 4 weeks | 21021701L | 11 | 1268 |
| RVIGL-Cre: 4 weeks | 21021701L | 12 | 931 |
| RVAGL-Cre: 4 weeks | 21021701L | 13 | 652 |
| RVIGL-Cre: 4 weeks | 21021701L | 14 | 491 |
| RVIGL-Cre: 4 weeks | 21021701】 | 15 | 336 |


| RVAGL-Cre: 4 weeks | 21021701L | total: | 19156 |
| :---: | :---: | :---: | :---: |
| RVAGL-Cre: 4 weeks | 21021702L | 1 | 957 |
| RVAGL-Cre: 4 weeks | 21021702L | 2 | 1175 |
| RVAGL-Cre: 4 weeks | 21021702L | 3 | 1414 |
| RVAGL-Cre: 4 weeks | 21021702ப | 4 | 1470 |
| RVAGL-Cre: 4 weeks | 21021702L | 5 | 1481 |
| RVAGL-Cre: 4 weeks | 21021702L | 6 | 1654 |
| RVAGL-Cre: 4 weeks | 21021702ப | 7 | 1616 |
| RVDGL-Cre: 4 weeks | 21021702L | 8 | 1601 |
| RVAGL-Cre: 4 weeks | 21021702L | 9 | 1717 |
| RVAGL-Cre: 4 weeks | 21021702L | 10 | 1449 |
| RVDGL-Cre: 4 weeks | 21021702L | 11 | 1132 |
| RVAGL-Cre: 4 weeks | 21021702L | 12 | 871 |
| RVAGL-Cre: 4 weeks | 21021702L | 13 | 587 |
| RVAGL-Cre: 4 weeks | 21021702L | 14 | 456 |
| RVAGL-Cre: 4 weeks | 21021702L | 15 | 355 |
| RVAGL-Cre: 4 weeks | 21021702L | total: | 17935 |
| RVAGL-Cre: 4 weeks | 21021705L | 1 | 892 |
| RVAGL-Cre: 4 weeks | 21021705L | 2 | 824 |
| RVAGL-Cre: 4 weeks | 21021705L | 3 | 879 |
| RVAGL-Cre: 4 weeks | 21021705L | 4 | 1094 |
| RVAGL-Cre: 4 weeks | 21021705L | 5 | 1182 |
| RVDGL-Cre: 4 weeks | 21021705L | 6 | 1318 |
| RVAGL-Cre: 4 weeks | 21021705L | 7 | 1482 |
| RVAGL-Cre: 4 weeks | 21021705L | 8 | 1637 |
| RVAGL-Cre: 4 weeks | 21021705L | 9 | 1666 |
| RVAGL-Cre: 4 weeks | 21021705L | 10 | 1796 |
| RVAGL-Cre: 4 weeks | 21021705L | 11 | 1636 |
| RVDGL-Cre: 4 weeks | 21021705L | 12 | 1415 |
| RVAGL-Cre: 4 weeks | 21021705L | 13 | 1121 |
| RVAGL-Cre: 4 weeks | 21021705L | 14 | 894 |
| RVAGL-Cre: 4 weeks | 21021705L | 15 | 703 |
| RVDGL-Cre: 4 weeks | 21021705L | total: | 18539 |
| RVDGL-Cre: 4 weeks | 21021706L | 1 | 756 |
| RVDGL-Cre: 4 weeks | 21021706L | 2 | 817 |
| RVAGL-Cre: 4 weeks | 21021706L | 3 | 750 |
| RVAGL-Cre: 4 weeks | 21021706L | 4 | 798 |
| RVDGL-Cre: 4 weeks | 21021706L | 5 | 920 |
| RVAGL-Cre: 4 weeks | 21021706L | 6 | 1337 |
| RVDGL-Cre: 4 weeks | 21021706L | 7 | 1485 |
| RVDGL-Cre: 4 weeks | 21021706L | 8 | 1490 |
| RVAGL-Cre: 4 weeks | 21021706L | 9 | 1641 |
| RVAGL-Cre: 4 weeks | 21021706L | 10 | 2004 |
| RVAGL-Cre: 4 weeks | 21021706L | 11 | 1955 |
| RVAGL-Cre: 4 weeks | 21021706L | 12 | 1453 |
| RVAGL-Cre: 4 weeks | 21021706L | 13 | 1122 |
| RVDGL-Cre: 4 weeks | 21021706L | 14 | 769 |
| RVAGL-Cre: 4 weeks | 21021706L | 15 | 641 |
| RVAGL-Cre: 4 weeks | 21021706L | total: | 17938 |
| RVAL-Cre: 4 weeks | 21021901L | 1 | 943 |
| RVAL-Cre: 4 weeks | 21021901L | 2 | 1003 |
| RVAL-Cre: 4 weeks | 21021901L | 3 | 1036 |
| RVAL-Cre: 4 weeks | 21021901L | 4 | 1195 |
| RVAL-Cre: 4 weeks | 21021901L | 5 | 1402 |
| RVAL-Cre: 4 weeks | 21021901L | 6 | 1739 |


| RVAL-Cre: 4 weeks | 21021901L | 7 | 1793 |
| :---: | :---: | :---: | :---: |
| RVAL-Cre: 4 weeks | 21021901L | 8 | 1913 |
| RVAL-Cre: 4 weeks | 21021901L | 9 | 2026 |
| RVAL-Cre: 4 weeks | 21021901L | 10 | 1913 |
| RVAL-Cre: 4 weeks | 21021901L | 11 | 1929 |
| RVAL-Cre: 4 weeks | 21021901L | 12 | 1668 |
| RVAL-Cre: 4 weeks | 21021901L | 13 | 1247 |
| RVAL-Cre: 4 weeks | 21021901L | 14 | 1062 |
| RVAL-Cre: 4 weeks | 21021901L | 15 | 874 |
| RVAL-Cre: 4 weeks | 21021901L | total: | 21743 |
| RVAL-Cre: 4 weeks | 21021902 J | 1 | 1357 |
| RVAL-Cre: 4 weeks | 21021902L | 2 | 1416 |
| RVAL-Cre: 4 weeks | 21021902L | 3 | 1287 |
| RVAL-Cre: 4 weeks | 21021902 $Ј$ | 4 | 1308 |
| RVAL-Cre: 4 weeks | 21021902L | 5 | 1583 |
| RVAL-Cre: 4 weeks | 21021902 $Ј$ | 6 | 1850 |
| RVAL-Cre: 4 weeks | 21021902 J | 7 | 2020 |
| RVAL-Cre: 4 weeks | 21021902L | 8 | 2238 |
| RVAL-Cre: 4 weeks | 21021902L | 9 | 2092 |
| RVAL-Cre: 4 weeks | 21021902 J | 10 | 2321 |
| RVAL-Cre: 4 weeks | 21021902L | 11 | 2241 |
| RVAL-Cre: 4 weeks | 21021902 J | 12 | 1858 |
| RVAL-Cre: 4 weeks | 21021902 J | 13 | 1326 |
| RVAL-Cre: 4 weeks | 21021902L | 14 | 1083 |
| RVAL-Cre: 4 weeks | 21021902 J | 15 | 793 |
| RVAL-Cre: 4 weeks | 21021902 J | total: | 24773 |
| RVAL-Cre: 4 weeks | 21021903L | 1 | 1543 |
| RVAL-Cre: 4 weeks | 21021903L | 2 | 1406 |
| RVAL-Cre: 4 weeks | 21021903L | 3 | 1303 |
| RVAL-Cre: 4 weeks | 21021903L | 4 | 1489 |
| RVAL-Cre: 4 weeks | 21021903L | 5 | 1825 |
| RVAL-Cre: 4 weeks | 21021903L | 6 | 1946 |
| RVAL-Cre: 4 weeks | 21021903L | 7 | 1924 |
| RVAL-Cre: 4 weeks | 21021903L | 8 | 2142 |
| RVAL-Cre: 4 weeks | 21021903L | 9 | 2077 |
| RVAL-Cre: 4 weeks | 21021903L | 10 | 1954 |
| RVAL-Cre: 4 weeks | 21021903L | 11 | 1672 |
| RVAL-Cre: 4 weeks | 21021903L | 12 | 1411 |
| RVAL-Cre: 4 weeks | 21021903L | 13 | 1020 |
| RVAL-Cre: 4 weeks | 21021903L | 14 | 687 |
| RVAL-Cre: 4 weeks | 21021903L | 15 | 627 |
| RVAL-Cre: 4 weeks | 21021903L | total: | 23026 |
| RVAL-Cre: 4 weeks | 21021904L | 1 | 1592 |
| RVAL-Cre: 4 weeks | 21021904 ${ }^{\text {J }}$ | 2 | 1466 |
| RVAL-Cre: 4 weeks | 21021904L | 3 | 1355 |
| RVAL-Cre: 4 weeks | 21021904 ${ }^{\text {J }}$ | 4 | 1599 |
| RVAL-Cre: 4 weeks | 21021904 J | 5 | 1736 |
| RVAL-Cre: 4 weeks | 21021904L | 6 | 1862 |
| RVAL-Cre: 4 weeks | 21021904 ${ }^{\text {J }}$ | 7 | 1794 |
| RVAL-Cre: 4 weeks | 21021904 J | 8 | 1930 |
| RVAL-Cre: 4 weeks | 21021904L | 9 | 2047 |
| RVAL-Cre: 4 weeks | 21021904 ${ }^{\text {J }}$ | 10 | 1584 |
| RVAL-Cre: 4 weeks | 21021904 | 11 | 1755 |
| RVAL-Cre: 4 weeks | 21021904 J | 12 | 1431 |
| RVAL-Cre: 4 weeks | 21021904 $\downarrow$ | 13 | 741 |


| RVDL-Cre: 4 weeks | 21021904L | 14 | 755 |
| :---: | :---: | :---: | :---: |
| RVIL-Cre: 4 weeks | 21021904L | 15 | 625 |
| RVIL-Cre: 4 weeks | 21021904L | total: | 22272 |
| RVIL-5tTA: 1 week | 21042901L | 3 | 2 |
| RVIL-5tTA: 1 week | 21042901L | 6 | 9 |
| RVIL-5tTA: 1 week | 21042901L | 7 | 4 |
| RVIL-5tTA: 1 week | 21042901L | 8 | 26 |
| RVIL-5tTA: 1 week | 21042901L | 9 | 32 |
| RVIL-5tTA: 1 week | 21042901L | 10 | 54 |
| RVIL-5tTA: 1 week | 21042901L | 11 | 69 |
| RVIL-5tTA: 1 week | 21042901L | 12 | 56 |
| RVIL-5tTA: 1 week | 21042901L | 13 | 51 |
| RVIL-5tTA: 1 week | 21042901L | 14 | 14 |
| RVIL-5tTA: 1 week | 21042901L | 15 | 22 |
| RVIL-5tTA: 1 week | 21042901L | total: | 339 |
| RVDL-5tTA: 1 week | 21042902LJ | 1 | 4 |
| RVIL-5tTA: 1 week | 21042902L | 2 | 11 |
| RVIL-5tTA: 1 week | 21042902L | 3 | 14 |
| RVIL-5tTA: 1 week | 21042902L | 4 | 4 |
| RVIL-5tTA: 1 week | 21042902L | 5 | 39 |
| RVIL-5tTA: 1 week | 21042902L | 6 | 108 |
| RVIL-5tTA: 1 week | 21042902L | 7 | 213 |
| RVIL-5tTA: 1 week | 21042902L | 8 | 255 |
| RVIL-5tTA: 1 week | 21042902L | 9 | 296 |
| RVIL-5tTA: 1 week | 21042902L | 10 | 219 |
| RVIL-5tTA: 1 week | 21042902 | 11 | 134 |
| RVDL-5tTA: 1 week | 21042902L | 12 | 64 |
| RVIL-5tTA: 1 week | 21042902L | 13 | 29 |
| RVIL-5tTA: 1 week | 21042902L | 14 | 14 |
| RVIL-5tTA: 1 week | 21042902L | 15 | 7 |
| RVIL-5tTA: 1 week | 21042902L | total: | 1411 |
| RVIL-5tTA: 1 week | 21042903L | 2 | 3 |
| RVDL-5tTA: 1 week | 21042903L | 3 | 7 |
| RVIL-5tTA: 1 week | 21042903L | 4 | 6 |
| RVIL-5tTA: 1 week | 21042903L | 5 | 4 |
| RVIL-5tTA: 1 week | 21042903L | 6 | 27 |
| RVIL-5tTA: 1 week | 21042903L | 7 | 40 |
| RVDL-5tTA: 1 week | 21042903L | 8 | 81 |
| RVIL-5tTA: 1 week | 21042903L | 9 | 115 |
| RVIL-5tTA: 1 week | 21042903L | 10 | 165 |
| RVDL-5tTA: 1 week | 21042903L | 11 | 120 |
| RVIL-5tTA: 1 week | 21042903L | 12 | 84 |
| RVIL-5tTA: 1 week | 21042903L | 13 | 67 |
| RVDL-5tTA: 1 week | 21042903L | 14 | 44 |
| RVIL-5tTA: 1 week | 21042903L | 15 | 33 |
| RVIL-5tTA: 1 week | 21042903L | total: | 796 |
| RVDL-5tTA: 1 week | 21060301L | 1 | 85 |
| RVIL-5tTA: 1 week | 21060301L | 2 | 117 |
| RVIL-5tTA: 1 week | 21060301L | 3 | 154 |
| RVDL-5tTA: 1 week | 21060301L | 4 | 59 |
| RVIL-5tTA: 1 week | 21060301L | 5 | 207 |
| RVIL-5tTA: 1 week | 21060301L | 6 | 325 |
| RVIL-5tTA: 1 week | 21060301L | 7 | 314 |
| RVIL-5tTA: 1 week | 21060301L | 8 | 303 |
| RVIL-5tTA: 1 week | 21060301L | 9 | 288 |


| RVAL-5tTA: 1 week | 21060301L | 10 | 185 |
| :---: | :---: | :---: | :---: |
| RVAL-5tTA: 1 week | 21060301L | 11 | 141 |
| RVIL-5tTA: 1 week | 21060301L | 12 | 47 |
| RVIL-5tTA: 1 week | 21060301L | 13 | 19 |
| RVAL-5tTA: 1 week | 21060301L | 14 | 14 |
| RVAL-5tTA: 1 week | 21060301L | 15 | 13 |
| RVAL-5tTA: 1 week | 21060301L | total: | 2271 |
| RVIL-5tTA: 4 weeks | 21042905L | 1 | 4 |
| RVIL-5tTA: 4 weeks | 21042905L | 2 | 14 |
| RVIL-5tTA: 4 weeks | 21042905L | 3 | 6 |
| RVAL-5tTA: 4 weeks | 21042905L | 4 | 21 |
| RVIL-5tTA: 4 weeks | 21042905L | 5 | 15 |
| RVIL-5tTA: 4 weeks | 21042905L | 6 | 41 |
| RVAL-5tTA: 4 weeks | 21042905L | 7 | 42 |
| RVIL-5tTA: 4 weeks | 21042905L | 8 | 101 |
| RVAL-5tTA: 4 weeks | 21042905L | 9 | 156 |
| RVAL-5tTA: 4 weeks | 21042905L | 10 | 109 |
| RVIL-5tTA: 4 weeks | 21042905L | 11 | 94 |
| RVIL-5tTA: 4 weeks | 21042905L | 12 | 24 |
| RVAL-5tTA: 4 weeks | 21042905L | 13 | 87 |
| RVIL-5tTA: 4 weeks | 21042905L | 14 | 44 |
| RVAL-5tTA: 4 weeks | 21042905L | 15 | 71 |
| RVAL-5tTA: 4 weeks | 21042905L | total: | 829 |
| RVAL-5tTA: 4 weeks | 21042906L | 1 | 9 |
| RVIL-5tTA: 4 weeks | 21042906L | 2 | 17 |
| RVIL-5tTA: 4 weeks | 21042906L | 3 | 28 |
| RVAL-5tTA: 4 weeks | 21042906L | 4 | 23 |
| RVAL-5tTA: 4 weeks | 21042906L | 5 | 24 |
| RVIL-5tTA: 4 weeks | 21042906L | 6 | 25 |
| RVIL-5tTA: 4 weeks | 21042906L | 7 | 93 |
| RVAL-5tTA: 4 weeks | 21042906L | 8 | 200 |
| RVAL-5tTA: 4 weeks | 21042906L | 9 | 305 |
| RVAL-5tTA: 4 weeks | 21042906L | 10 | 233 |
| RVAL-5tTA: 4 weeks | 21042906L | 11 | 200 |
| RVIL-5tTA: 4 weeks | 21042906L | 12 | 141 |
| RVIL-5tTA: 4 weeks | 21042906L | 13 | 74 |
| RVIL-5tTA: 4 weeks | 21042906L | 14 | 108 |
| RVAL-5tTA: 4 weeks | 21042906L | 15 | 94 |
| RVAL-5tTA: 4 weeks | 21042906L | total: | 1574 |
| RVAL-5tTA: 4 weeks | 21042907ப | 2 | 2 |
| RVIL-5tTA: 4 weeks | 21042907ப | 4 | 3 |
| RVAL-5tTA: 4 weeks | 21042907 | 5 | 5 |
| RVAL-5tTA: 4 weeks | 21042907 | 6 | 24 |
| RVAL-5tTA: 4 weeks | 21042907 | 7 | 32 |
| RVAL-5tTA: 4 weeks | 21042907 | 8 | 51 |
| RVIL-5tTA: 4 weeks | 21042907ப | 9 | 100 |
| RVAL-5tTA: 4 weeks | 21042907 | 10 | 74 |
| RVAL-5tTA: 4 weeks | 21042907 | 11 | 69 |
| RVAL-5tTA: 4 weeks | 21042907 | 12 | 54 |
| RVIL-5tTA: 4 weeks | 21042907 | 13 | 26 |
| RVIL-5tTA: 4 weeks | 21042907L | 14 | 31 |
| RVAL-5tTA: 4 weeks | 21042907ப | 15 | 28 |
| RVIL-5tTA: 4 weeks | 21042907U | total: | 499 |
| RVAL-5tTA: 4 weeks | 21042908L | 1 | 64 |
| RVAL-5tTA: 4 weeks | 21042908L | 2 | 67 |

bioRxiv preprint doi: https://doi.org/10.1101/2022.02.23.481706; this version posted April 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.

| RVIL-5tTA: 4 weeks | 21042908L | 3 | 66 |
| :---: | :---: | :---: | :---: |
| RVIL-5tTA: 4 weeks | 21042908L | 4 | 79 |
| RVIL-5tTA: 4 weeks | 21042908L | 5 | 151 |
| RVAL-5tTA: 4 weeks | 21042908L | 6 | 149 |
| RVIL-5tTA: 4 weeks | 21042908L | 7 | 166 |
| RVIL-5tTA: 4 weeks | 21042908L | 8 | 171 |
| RVIL-5tTA: 4 weeks | 21042908L | 9 | 184 |
| RVIL-5tTA: 4 weeks | 21042908L | 10 | 57 |
| RVIL-5tTA: 4 weeks | 21042908L | 11 | 48 |
| RVAL-5tTA: 4 weeks | 21042908L | 12 | 29 |
| RVIL-5tTA: 4 weeks | 21042908L | 13 | 14 |
| RVIL-5tTA: 4 weeks | 21042908L | 14 | 27 |
| RVIL-5tTA: 4 weeks | 21042908L | 15 | 57 |
| RVAL-5tTA: 4 weeks | 21042908L | total: | 1329 |


| Condition | Mouse number | Cell counts |
| :---: | :---: | :---: |
| RVAGL-Flpo: 1 week | 21021505LJ | 22 |
| RVAGL-Flpo: 1 week | 21021506LJ | 18 |
| RVAGL-Flpo: 1 week | 21021507LJ | 121 |
| RVAGL-Flpo: 1 week | 21021508L | 2 |
| RVAGL-Flpo: 1 week | 21052505LJ | 7 |
| RVAGL-Flpo: 1 week | 21052506LJ | 8 |
| RVAGL-Flpo: 1 week | 21052507LJ | 98 |
| RVAGL-Flpo: 1 week | 21052508LJ | 6 |
| RVAGL-Flpo: 1 week | Mean: | 35.25 |
| RVAL-Flpo: 1 week | 21021805LJ | 3093 |
| RVAL-Flpo: 1 week | 21021806LJ | 320 |
| RVAL-Flpo: 1 week | 21021807L | 311 |
| RVAL-Flpo: 1 week | 21021808L | 263 |
| RVAL-Flpo: 1 week | 21052607LJ | 47 |
| RVAL-Flpo: 1 week | 21052608LJ | 2161 |
| RVAL-Flpo: 1 week | 21060302L | 365 |
| RVAL-Flpo: 1 week | 21060303LJ | 238 |
| RVAL-Flpo: 1 week | Mean: | 849.75 |
| RVAGL-Flpo: 4 weeks | 21021501LJ | 80 |
| RVAGL-Flpo: 4 weeks | 21021502LJ | 62 |
| RVAGL-Flpo: 4 weeks | 21021503LJ | 3254 |
| RVAGL-Flpo: 4 weeks | 21021504LJ | 237 |
| RVAGL-Flpo: 4 weeks | 21052501LJ | 43 |
| RVAGL-Flpo: 4 weeks | 21052502LJ | 14 |
| RVAGL-Flpo: 4 weeks | 21052503LJ | 130 |
| RVAGL-Flpo: 4 weeks | 21052504LJ | 65 |
| RVAGL-Flpo: 4 weeks | Mean: | 485.625 |
| RVIL-Flpo: 4 weeks | 21021801LJ | 4614 |
| RVIL-Flpo: 4 weeks | 21021802 J | 3006 |
| RVIL-Flpo: 4 weeks | 21021803LJ | 1847 |
| RVIL-Flpo: 4 weeks | 21021804LJ | 3331 |
| RVIL-Flpo: 4 weeks | 21052601LJ | 1369 |
| RVIL-Flpo: 4 weeks | 21052602LJ | 2919 |
| RVIL-Flpo: 4 weeks | 21052603LJ | 3730 |
| RVIL-Flpo: 4 weeks | 21052606LJ | 3454 |
| RVIL-Flpo: 4 weeks | Mean: | 3033.75 |
| RVAGL-Cre: 1 week | 21021703LJ | 13484 |
| RVAGL-Cre: 1 week | 21021704LJ | 14635 |
| RVAGL-Cre: 1 week | 21021707LJ | 10647 |
| RVAGL-Cre: 1 week | 21021708LJ | 10845 |
| RVDGL-Cre: 1 week | Mean: | 12402.75 |
| RVAL-Cre: 1 week | 21021905L | 16907 |
| RVAL-Cre: 1 week | 21021906LJ | 17923 |
| RVAL-Cre: 1 week | 21021907ப | 18751 |
| RVAL-Cre: 1 week | 21021908L | 16257 |
| RVAL-Cre: 1 week | Mean: | 17459.5 |
| RVAGL-Cre: 4 weeks | 21021701L | 19156 |
| RVAGL-Cre: 4 weeks | 21021702LJ | 17935 |
| RVAGL-Cre: 4 weeks | 21021705L | 18539 |
| RVAGL-Cre: 4 weeks | 21021706LJ | 17938 |
| RVAGL-Cre: 4 weeks | Mean: | 18392 |
| RVAL-Cre: 4 weeks | 21021901L | 21743 |
| RVDL-Cre: 4 weeks | 21021902LJ | 24773 |
| RVAL-Cre: 4 weeks | 21021903LJ | 23026 |
| RVDL-Cre: 4 weeks | 21021904 J | 22272 |
| RVDL-Cre: 4 weeks | Mean: | 22953.5 |
| RVAL-5tTA: 1 week | 21042901L | 339 |
| RVAL-5tTA: 1 week | 21042902LJ | 1411 |
| RVAL-5tTA: 1 week | 21042903LJ | 796 |
| RVAL-5tTA: 1 week | 21060301L | 2271 |
| RVAL-5tTA: 1 week | Mean: | 1204.25 |
| RVDL-5tTA: 4 weeks | 21042905LJ | 829 |
| RVAL-5tTA: 4 weeks | 21042906L | 1574 |
| RVAL-5tTA: 4 weeks | 21042907L | 499 |
| RVAL-5tTA: 4 weeks | 21042908L | 1329 |
| RVILL-5tTA: 4 weeks | Mean: | 1057.75 |


| RVDGL-Flpo 4 weeks | RVDL-Flpo 4 weeks |
| :--- | :--- |
| 80 | 4614 |
| 62 | 3006 |
| 3254 | 1847 |
| 237 | 3331 |
| 43 | 1369 |
| 14 | 2919 |
| 130 | 3730 |
| 65 | 3454 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta$ GL-Flpo 4 weeks | 8 | 3885 | 485.625 | 1255920.84 |
| RVDL-Flpo 4 weeks | 8 | 24270 | 3033.75 | 1062946.79 |

ANOVA

| Source of Variation | SS | $d f$ | MS | F | P-value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 25971764.06 | 1 | 25971764.1 | 22.4003852 | 0.00032063 | 4.60010994 |
| Within Groups | 16232073.38 | 14 | 1159433.81 |  |  |  |
|  |  |  |  |  |  |  |
| Total | 42203837.44 | 15 |  |  |  |  |


| RV $\Delta$ GL-Flpo 1 week | RV $\Delta$ GL-Flpo 4 weeks |
| :--- | :--- |
| 22 | 80 |
| 18 | 62 |
| 121 | 3254 |
| 2 | 237 |
| 7 | 43 |
| 8 | 14 |
| 98 | 130 |
| 6 | 65 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta$ GL-Flpo 1 week | 8 | 282 | 35.25 | 2180.78571 |
| RV GL-Flpo 4 weeks | 8 | 3885 | 485.625 | 1255920.84 |

ANOVA

| Source of Variation | SS | $d f$ | MS | F | -value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 811350.5625 | 1 | 811350.563 | 1.28980131 | 0.27515341 | 4.60010994 |
| Within Groups | 8806711.375 | 14 | 629050.813 |  |  |  |
|  |  |  |  |  |  |  |
| Total | 9618061.938 | 15 |  |  |  |  |


| RVAGL-Flpo 4 weeks | RVDL-Flpo 1 week |
| :--- | :--- |
| 80 | 3093 |
| 62 | 320 |
| 3254 | 311 |
| 237 | 263 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta$ GL-Flpo 4 weeks | 4 | 3633 | 908.25 | 2451752.25 |
| RVDL-Flpo 1 week | 4 | 3987 | 996.75 | 1953632.25 |

ANOVA

| Source of Variation | SS | $d f$ | MS | $F$ | $P$-value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 15664.5 | 1 | 15664.5 | 0.00711152 | 0.93553752 | 5.98737761 |
| Within Groups | 13216153.5 | 6 | 2202692.25 |  |  |  |
|  |  |  |  |  |  |  |
| Total | 13231818 | 7 |  |  |  |  |


| RVDL-Flpo 4 weeks | RVAGL-Flpo 1 week |
| :--- | :--- |
| 4614 | 22 |
| 3006 | 18 |
| 1847 | 121 |
| 3331 | 2 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RVDL-Flpo 4 weeks | 4 | 12798 | 3199.5 | 1294933.67 |
| RVDGL-Flpo 1 week | 4 | 163 | 40.75 | 2936.91667 |
|  |  |  |  |  |

ANOVA

| Source of Variation | SS | $d f$ | MS | F | P-value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 19955403.13 | 1 | 19955403.1 | 30.7509907 | 0.00145233 | 5.98737761 |
| Within Groups | 3893611.75 | 6 | 648935.292 |  |  |  |
|  |  |  |  |  |  |  |
| Total | 23849014.88 | 7 |  |  |  |  |


| RVDL-Flpo 1 week | RVDL-Flpo 4 weeks |
| :--- | :--- |
| 3093 | 4614 |
| 320 | 3006 |
| 311 | 1847 |
| 263 | 3331 |
| 47 | 1369 |
| 2161 | 2919 |
| 365 | 3730 |
| 238 | 3454 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RVAL-Flpo 1 week | 8 | 6798 | 849.75 | 1274333.93 |
| RVAL-Flpo 4 weeks | 8 | 24270 | 3033.75 | 1062946.79 |


| ANOVA |  |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Source of Variation | SS | 1 | MS | F | -value | F crit |
| Between Groups | 19079424 | 14 | 19079424 | 16.3261724 | 0.00121549 | 4.60010994 |
| Within Groups | 16360965 |  | 1168640.36 |  |  |  |
| Total | 35440389 | 15 |  |  |  |  |


| RVAGL-Flpo 1 week | RVAL-Flpo 1 week |
| :--- | :--- |
| 22 | 3093 |
| 18 | 320 |
| 121 | 311 |
| 2 | 263 |
| 7 | 47 |
| 8 | 2161 |
| 98 | 365 |
| 6 | 238 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta$ GL-Flpo 1 week | 8 | 282 | 35.25 | 2180.78571 |
| RVDL-Flpo 1 week | 8 | 6798 | 849.75 | 1274333.93 |

ANOVA

| Source of Variation | SS | $d f$ | MS | F | $P$-value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 2653641 | 1 | 2653641 | 4.1576348 | 0.06079134 | 4.60010994 |
| Within Groups | 8935603 | 14 | 638257.357 |  |  |  |
|  |  | 11589244 | 15 |  |  |  |
| Total |  |  |  |  |  |  |


| RVDGL-Cre 4 weeks | RVDL-Cre 4 weeks |
| :--- | :--- |
| 19156 | 21743 |
| 17935 | 24773 |
| 18539 | 23026 |
| 17938 | 22272 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta$ GL-Cre 4 weeks | 4 | 73568 | 18392 | 340090 |
| RV $\Delta$ L-Cre 4 weeks | 4 | 91814 | 22953.5 | 1748529.67 |


| ANOVA |  |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Source of Variation | SS | df | MS | F | P-value | F crit |
| Between Groups | 41614564.5 | 1 | 41614564.5 | 39.8488678 | 0.00073769 | 5.98737761 |
| Within Groups | 6265859 | 6 | 1044309.83 |  |  |  |
| Total | 47880423.5 | 7 |  |  |  |  |


| RVDGL-Cre 4 weeks | RVDGL-Cre 1 week |
| :--- | :--- |
| 19156 | 13484 |
| 17935 | 14635 |
| 18539 | 10647 |
| 17938 | 10845 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta$ GL-Cre 4 weeks | 4 | 73568 | 18392 | 340090 |
| RV $\Delta$ GL-Cre 1 week | 4 | 49611 | 12402.75 | 3887094.92 |

ANOVA

| Source of Variation | SS | df | MS | F | $P$-value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 71742231.13 | 1 | 71742231.1 | 33.943266 | 0.00112486 | 5.98737761 |
| Within Groups | 12681554.75 | 6 | 2113592.46 |  |  |  |
|  |  |  |  |  |  |  |
| Total | 84423785.88 | 7 |  |  |  |  |


| RVDGL-Cre 4 weeks | RVDL-Cre 1 week |
| :--- | :--- |
| 19156 | 16907 |
| 17935 | 17923 |
| 18539 | 18751 |
| 17938 | 16257 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta$ GL-Cre 4 weeks | 4 | 73568 | 18392 | 340090 |
| RV $\Delta$ L-Cre 1 week | 4 | 69838 | 17459.5 | 1211355.67 |

ANOVA

| Source of Variation | SS | $d f$ | MS | $F$ | $P$-value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 1739112.5 | 1 | 1739112.5 | 2.24192511 | 0.1849584 | 5.98737761 |
| Within Groups | 4654337 |  | 6 | 775722.833 |  |  |
|  |  |  |  |  |  |  |
| Total | 6393449.5 | 7 |  |  |  |  |


| RVDL-Cre 4 weeks | RV $\Delta$ GL-Cre 1 week |
| :--- | :--- |
| 21743 | 13484 |
| 24773 | 14635 |
| 23026 | 10647 |
| 22272 | 10845 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta$ L-Cre 4 weeks | 4 | 91814 | 22953.5 | 1748529.67 |
| RV $\Delta$ GL-Cre 1 week | 4 | 49611 | 12402.75 | 3887094.92 |

ANOVA

| Source of Variation | SS | $d f$ | MS | F | $P$-value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 222636651.1 | 1 | 222636651 | 79.010462 | 0.00011291 | 5.98737761 |
| Within Groups | 16906873.75 | 6 | 2817812.29 |  |  |  |
|  |  |  |  |  |  |  |
| Total | 239543524.9 | 7 |  |  |  |  |


| RVDL-Cre 4 weeks | RVDL-Cre 1 week |
| :--- | :--- |
| 21743 | 16907 |
| 24773 | 17923 |
| 23026 | 18751 |
| 22272 | 16257 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta$ L-Cre 4 weeks | 4 | 91814 | 22953.5 | 1748529.67 |
| RV $\Delta$ L-Cre 1 week | 4 | 69838 | 17459.5 | 1211355.67 |

ANOVA

| Source of Variation | SS | $d f$ | MS | F | P-value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 60368072 | 1 | 60368072 | 40.790818 | 0.00069327 | 5.98737761 |
| Within Groups | 8879656 |  | 6 | 1479942.67 |  |  |
|  |  | 7 |  |  |  |  |
| Total | 69247728 |  |  |  |  |  |

RVDGL-Cre 1 week RVDL-Cre 1 week

| 13484 | 16907 |
| :--- | :--- |
| 14635 | 17923 |
| 10647 | 18751 |
| 10845 | 16257 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta$ GL-Cre 1 week | 4 | 49611 | 12402.75 | 3887094.92 |
| RV $\Delta$ L-Cre 1 week | 4 | 69838 | 17459.5 | 1211355.67 |

ANOVA

| Source of Variation | SS | $d f$ | MS | $F$ | $P$-value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 51141441.13 | 1 | 51141441.1 | 20.061562 | 0.00419681 | 5.98737761 |
| Within Groups | 15295351.75 | 6 | 2549225.29 |  |  |  |
|  |  |  |  |  |  |  |
| Total | 66436792.88 | 7 |  |  |  |  |


| RV $\Delta L-5 t T A ~ 1 ~ w e e k ~$ | RV $\Delta L-5 t T A ~ 4 ~ w e e k s ~$ |
| :--- | :--- |
| 339 | 829 |
| 1411 | 1574 |
| 796 | 499 |
| 2271 | 1329 |

Anova: Single Factor

SUMMARY

| Groups | Count | Sum | Average | Variance |
| :--- | :--- | :--- | :--- | :--- |
| RV $\Delta L-5 t T A ~ 1 ~ w e e k ~$ | 4 | 4817 | 1204.25 | 698675.583 |
| RV $\Delta$ L-5tTA 4 weeks | 4 | 4231 | 1057.75 | 234872.917 |

ANOVA

| Source of Variation | SS | df | MS | F | P-value | F crit |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Between Groups | 42924.5 | 1 | 42924.5 | 0.09195987 | 0.77193993 | 5.98737761 |
| Within Groups | 2800645.5 | 6 | 466774.25 |  |  |  |
|  |  |  |  |  |  |  |
| Total | 2843570 |  |  |  |  |  |


| Comparison | p-value |
| :---: | :---: |
| RVAGL-Flpo 4 weeks vs RVDL-Flpo 4 weeks | 0.000320625 |
| RVAGL-Flpo 4 weeks vs RVAGL-Flpo 1 week | 0.27515341 |
| RVAGL-Flpo 4 weeks vs RVAL-Flpo 1 week | 0.93553752 |
| RVDL-Flpo 4 weeks vs RVAGL-Flpo 1 week | 0.001452333 |
| RVAL-Flpo 4 weeks vs RVAL-Flpo 1 week | 0.001215493 |
| RVAGL-Flpo 1 week vs RVAL-Flpo 1 week | 0.060791343 |
| RVDGL-Cre 4 weeks vs RVDL-Cre 4 weeks | 0.000737695 |
| RVAGL-Cre 4 weeks vs RVDGL-Cre 1 week | 0.001124862 |
| RVDGL-Cre 4 weeks vs RVDL-Cre 1 weeks | 0.184958403 |
| RVAL-Cre 4 weeks vs RVAGL-Cre 1 week | 0.000112909 |
| RVDL-Cre 4 weeks vs RV $\Delta$ L-Cre 1 week | 0.000693266 |
| RVAGL-Cre 1 week vs RVDL-Cre 1 week | 0.004196815 |
| RVIL-5tTA 1 week vs RV $\Delta L$-5tTA 4 weeks | 0.77193993 |

## Video S1. RV $\Delta$ L-Cre-labeled cortical neurons at 2 weeks vs 10 weeks postinjection, Related to

 Figure 3814 3-dimensional rendering of the same cortical volume shown in Figure 3, panel B.

File S3. Cell counts and statistics for structural two-photon imaging experiments, Related to Figure 3

See following pages.
bioRxiv preprint doi: https://doi.org/10.1101/2022.02.23.481706; this version posted April 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.

| RVAGL-Cre: cell counts | Animal-1 FOV-1 | Animal-1 FOV-2 | Animal-2 FOV-1 | Animal-2 FOV-2 | Animal-3 FOV-1 | Animal-3 FOV-2 | Animal-4 FOV-1 | Animal-4 FOV-2 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Week-1 | 300 | 315 | 219 | 318 | 435 | 288 | 203 | 220 |
| Week-2 | 519 | 359 | 269 | 546 | 488 | 364 | 321 | 354 |
| Week-3 | 537 | 390 | 305 | 569 | 505 | 443 | 369 | 427 |
| Week-4 | 538 | 403 | 317 | 572 | 518 | 445 | 372 | 426 |
| Week-6 | 537 | 403 | 319 | 571 | 515 | 451 | 370 | 424 |
| Week-12 | 535 | 400 | 319 | 567 | 514 | 443 | 369 | 424 |
| Week-14 |  |  | 319 | 567 | 513 | 442 | 368 | 421 |
| Week-16 |  |  | 319 |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| RV $\triangle$ GL-Cre: percentage to week-1 | Animal-1 FOV-1 | Animal-1 FOV-2 | Animal-2 FOV-1 | Animal-2 FOV-2 | Animal-3 FOV-1 | Animal-3 FOV-2 | Animal-4 FOV-1 | Animal-4 FOV-2 |
| Week-1 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Week-2 | 1.73 | 1.14 | 1.23 | 1.72 | 1.12 | 1.26 | 1.58 | 1.61 |
| Week-3 | 1.79 | 1.24 | 1.39 | 1.79 | 1.16 | 1.54 | 1.82 | 1.94 |
| Week-4 | 1.79 | 1.28 | 1.45 | 1.80 | 1.19 | 1.55 | 1.83 | 1.94 |
| Week-6 | 1.79 | 1.28 | 1.46 | 1.80 | 1.18 | 1.57 | 1.82 | 1.93 |
| Week-12 | 1.78 | 1.27 | 1.46 | 1.78 | 1.18 | 1.54 | 1.82 | 1.93 |
| Week-14 |  |  | 1.46 | 1.78 | 1.18 | 1.53 | 1.81 | 1.91 |
| Week-16 |  |  | 1.46 |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| RVAGL-Cre: comparison between week-1 and week-4 | Animal-1 FOV-1 | Animal-1 FOV-2 | Animal-2 FOV-1 | Animal-2 FOV-2 | Animal-3 FOV-1 | Animal-3 FOV-2 | Animal-4 FOV-1 | Animal-4 FOV-2 |
| Week-1 | 300 | 315 | 219 | 318 | 435 | 288 | 203 | 220 |
| Week-4 | 538 | 403 | 317 | 572 | 518 | 445 | 372 | 426 |
| Increase (Week-4 - Week-1) | 238 | 88 | 98 | 254 | 83 | 157 | 169 | 206 |
| \% increase (Week-4 - Week-1) | 79.33\% | 27.94\% | 44.75\% | 79.87\% | 19.08\% | 54.51\% | 83.25\% | 93.64\% |
| Increase (Week-12 - Week-4) | -3 | -3 | 2 | -5 | -4 | -2 | -3 | -2 |
| \% increase (Week-12 - Week-4) | -0.56\% | -0.74\% | 0.63\% | -0.87\% | -0.77\% | -0.45\% | -0.81\% | -0.47\% |


| $\mathbf{t}$-Test: Paired Two Sample for Means |  |  |
| :---: | :---: | :---: |
| Mean | Week-1 | Week-4 |
| Variance | 287.25 | 448.875 |
| Observations | 5712.5 | 7689.267857 |
| Pearson Correlation | 8 | 8 |
| Hypothesized Mean Difference | 0.665513457 |  |
| df | 0 |  |
| t Stat | 7 |  |
| $\mathrm{P}(\mathrm{T}<\mathrm{t})$ one-tail | -6.75473154 |  |
| t Critical one-tail | $\mathbf{0 . 0 0 0 1 3 1 9 3 4}$ |  |
| $\mathrm{P}(\mathrm{T}<\mathrm{t})$ two-tail | 1.894578605 |  |
| t Critical two-tail | 0.000263868 |  |


| t -Test: Paired Two Sample for Means |  |  |
| :---: | :---: | :---: |
| Mean | Week-4 | Week-12 |
| Variance | 448.875 | 446.375 |
| Observations | 7689.267857 | 7407.410714 |
| Pearson Correlation | 8 | 8 |
| Hypothesized Mean Difference | 0.999890399 |  |
| df | 0 |  |
| t Stat | 7 |  |
| $\mathrm{P}(\mathrm{T}<\mathrm{t})$ one-tail | 3.415650255 |  |
| t Critical one-tail | $\mathbf{0 . 0 0 5 6 0 0 7 1 6}$ |  |
| $\mathrm{P}(\mathrm{T}<\mathrm{t})$ two-tail | 1.894578605 |  |
| t Critical two-tail | 0.011201433 |  |


| \% increase from 1 week to 4 weeks: |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| RV $\triangle$ GL-Cre | 79.33\% | 27.94\% | 44.75\% | 79.87\% | 19.08\% | 54.51\% | 83.25\% | 93.64\% |
| RV $\mathrm{S}_{\text {L-Cre }}$ | 84.38\% | 84.41\% | 49.57\% | 70.25\% | 54.88\% | 67.66\% | 40.66\% | 93.26\% |


| Unpaired t test |  |
| :---: | :---: |
| Table Analyzed | \% increase |
| P value | 0.5187 |
| $P$ value summary | ns |
| Significantly different ( $\mathrm{P}<0.05$ )? | No |
| One- or two-tailed P value? | Two-tailed |
| t, df | t=0.6621, df=14 |
|  |  |
| How big is the difference? |  |
| Mean of RVAGL-Cre | 0.603 |
| Mean of RVAL-Cre | 0.6813 |
| Difference between means (B-A) $\pm$ SEM | $0.07836 \pm 0.1184$ |
| 95\% confidence interval | -0.1755 to 0.3322 |
| R squared (eta squared) | 0.03036 |
|  |  |
| $F$ test to compare variances |  |
| F, DFn, Dfd | 2.216, 7, 7 |
| $P$ value | 0.3158 |
| $P$ value summary | ns |
| Significantly different ( $\mathrm{P}<0.05$ )? | No |
|  |  |
| Data analyzed |  |
| Sample size, RVAGL-Cre | 8 |
| Sample size, RVAL-Cre | 8 |


| \% increase from 4 weeks to 12 weeks: |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| RV $\triangle$ GL-Cre | -0.56\% | -0.74\% | 0.63\% | -0.87\% | -0.77\% | -0.45\% | -0.81\% | -0.47\% |
| RV $\mathrm{S}_{\text {L-Cre }}$ | 0.48\% | -0.29\% | 2.31\% | -1.46\% | 3.30\% | 0.00\% | 0.78\% | 0.58\% |


| Unpaired t test |  |
| :---: | :---: |
| P value | 0.0451 |
| $P$ value summary | * |
| Significantly different ( $\mathrm{P}<0.05$ )? | Yes |
| One- or two-tailed P value? | Two-tailed |
| t, df | $\mathrm{t}=2.199, \mathrm{df}=14$ |
| How big is the difference? |  |
| Mean of RVAGL-Cre | -0.005054 |
| Mean of RVAL-Cre | 0.007135 |
| Difference between means (B-A) $\pm$ SEM | . $01219 \pm 0.005542$ |
| 95\% confidence interval | 0003030 to 0.02407 |
| R squared (eta squared) | 0.2568 |
|  |  |
| $F$ test to compare variances |  |
| F, DFn, Dfd | 9.402, 7, 7 |
| P value | 0.0085 |
| $P$ value summary | ** |
| Significantly different ( $\mathrm{P}<0.05$ )? | Yes |
|  |  |
| Data analyzed |  |
| Sample size, RVAGL-Cre | 8 |
| Sample size, RVAL-Cre | 8 |

bioRxiv preprint doi: https://doi.org/10.1101/2022.02.23.481706; this version posted April 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.

| RV $\triangle$ L-Cre: cell counts | Animal-1 FOV-1 | Animal-1 FOV-2 | Animal-2 FOV-1 | Animal-2 FOV-2 | Animal-3 FOV-1 | Animal-3 FOV-2 | Animal-4 FOV-1 | Animal-4 FOV-2 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Week-1 | 224 | 186 | 232 | 242 | 215 | 167 | 182 | 178 |
| Week-2 | 331 | 307 | 300 | 298 | 270 | 237 | 200 | 228 |
| Week-3 | 396 | 340 | 341 | 378 | 289 | 279 | 253 | 304 |
| Week-4 | 413 | 343 | 347 | 412 | 333 | 280 | 256 | 344 |
| Week-6 | 409 | 342 | 347 | 413 | 342 | 283 | 255 | 345 |
| Week-12 | 415 | 342 | 355 | 406 | 344 | 280 | 258 | 346 |
| Week 14 | 415 | 342 | 354 | 406 | 344 | 280 |  |  |
| Week-16 |  |  |  | 406 | 344 | 280 |  |  |


| RVAL-Cre: percentage to week-1 | Animal-1 FOV-1 | Animal-1 FOV-2 | Animal-2 FOV-1 | Animal-2 FOV-2 | Animal-3 FOV-1 | Animal-3 FOV-2 | Animal-4 FOV-1 | Animal-4 FOV-2 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Week-1 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Week-2 | 1.48 | 1.65 | 1.29 | 1.23 | 1.26 | 1.42 | 1.10 | 1.28 |
| Week-3 | 1.77 | 1.83 | 1.47 | 1.56 | 1.34 | 1.67 | 1.39 | 1.71 |
| Week-4 | 1.84 | 1.84 | 1.50 | 1.70 | 1.55 | 1.68 | 1.41 | 1.93 |
| Week-6 | 1.83 | 1.84 | 1.50 | 1.71 | 1.59 | 1.69 | 1.40 | 1.94 |
| Week-12 | 1.85 | 1.84 | 1.53 | 1.68 | 1.60 | 1.68 | 1.42 | 1.94 |
| Week 14 | 1.85 | 1.84 | 1.53 | 1.68 | 1.60 | 1.68 |  |  |
| Week-16 |  |  |  | 1.68 | 1.60 | 1.68 |  |  |


| RVAL-Cre: comparison between week-1 and week-4 | Animal-1 FOV-1 | Animal-1 FOV-2 | Animal-2 FOV-1 | Animal-2 FOV-2 | Animal-3 FOV-1 | Animal-3 FOV-2 | Animal-4 FOV-1 | Animal-4 FOV-2 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Week-1 | 224 | 186 | 232 | 242 | 215 | 167 | 182 | 178 |
| Week-4 | 413 | 343 | 347 | 412 | 333 | 280 | 256 | 344 |
| Increase (Week-4 - Week-1) | 189 | 157 | 115 | 170 | 118 | 113 | 74 | 166 |
| \% increase (Week-4 - Week-1) | 84.38\% | 84.41\% | 49.57\% | 70.25\% | 54.88\% | 67.66\% | 40.66\% | 93.26\% |
| Increase (Week-12-Week-4) | 2 | -1 | 8 | -6 | 11 | 0 | 2 | 2 |
| \% increase (Week-12 - Week-4) | 0.48\% | -0.29\% | 2.31\% | -1.46\% | 3.30\% | 0.00\% | 0.78\% | 0.58\% |


| t -Test: Paired Two Sample for Means |  |  |
| :---: | :---: | :---: |
| Mean | Week-1 | Week-4 |
| Variance | 203.25 | 341 |
| Observations | 799.6428571 | 3040.571429 |
| Pearson Correlation | 8 | 8 |
| Hypothesized Mean Difference | 0.754099973 |  |
| df | 0 |  |
| t Stat | 7 |  |
| $\mathrm{P}(\mathrm{T}<=\mathrm{t})$ one-tail | -10.09862351 |  |
| $\mathrm{t} \mathrm{Critical} \mathrm{one-tail}$ | $\mathbf{1 . 0 0 2 6 6 \mathrm { E } - 0 5}$ |  |
| $\mathrm{P}(\mathrm{T}<=\mathrm{t})$ two-tail | 1.894578605 |  |
| t Critical two-tail | $2.00531 \mathrm{E}-05$ |  |


| t-Test: Paired Two Sample for Means |  |  |
| :---: | :---: | :---: |
|  | Week-4 | Week-12 |
| Mean | 341 | 343.25 |
| Variance | 3040.571429 | 2928.785714 |
| Observations | 8 | 8 |
| Pearson Correlation | 0.995543784 |  |
| Hypothesized Mean Difference | 0 |  |
| df | 7 |  |
| t Stat | -1.210419877 |  |
| $\mathrm{P}(\mathrm{T}<=\mathrm{t})$ one-tail | 0.13269902 |  |
| t Critical one-tail | 1.894578605 |  |
| $\mathrm{P}(\mathrm{T}<=\mathrm{t})$ two-tail | 0.265398039 |  |
| t Critical two-tail | 2.364624252 |  |



Figure S4. GCaMP6s signals and tuning curves of 8 example V1 neurons at 16 weeks postinjection, Related to Figure 4
These data were obtained with drifting gratings presented at 12 directions of motion and 5 temporal frequencies, repeated 10 times (tuning curve: mean $\Delta F / F \pm$ s.e.m; GCaMP6s signals: mean $\Delta F / F$ ) at two different FOVs at the 16-week timepoint.

## A



Week 10



B











Figure S5. More examples showing long-term stability of orientation and temporal frequency tuning in RV $\Delta$ L-Cre labeled neurons, Related to Figure 4
(A) Maximum intensity projections of the same FOV at 4 weeks, 10 weeks, and 14 weeks postinjection. Scale bar: $100 \mu \mathrm{~m}$, applies to all images.
(B) Visual responses of the three circled cells in panel a measured at the three different timepoints. Data were obtained with drifting gratings presented at 12 directions of motion and 5 temporal frequencies (mean $\Delta F / F \pm$ s.e.m., averaged over 10 repeats).

843 Video S2. GCaMP6s signals of visual cortical neurons 16 weeks after injection of RV $\Delta L$-Cre, Related to Figure 4
Video shows responses to 10 repeats of drifting gratings at 12 directions of motion at one temporal frequency ( 1 Hz ) over a total of 480 seconds.

See external file.

